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Abstract 
I characterised performance of the Positron Emission Tomography (PET) and the 
Computed Tomography (CT) modules of the 2-ring Albira PET/SPECT/CT,  
a small-animal imaging platform. The evaluation of PET was done in 
concordance with the National Electrical Manufacturer’s Association (NEMA) 
NU4-2008 standard. The performance of the Albira CT was assessed using 
microCT phantom. As a way of verification of the results of the phantom studies, 
example images from the tri-modal PET/SPECT/CT experiment were analysed. 
Additionally, gamma counter was evaluated as a tool for measuring 
biodistribution of the radiolabelled probes ex vivo. 
18F-Fluoro-L-Thymidine (18F-FLT) was used in the investigation of the treatment 
response in the mouse models of pancreatic ductal adenocarcinoma (PDAC). 
Results from the two studies using mTOR and TGFβ inhibitors are reported.  
The mTOR inhibitor, rapamycin used 18F-FLT in the PET imaging to study, which 
aimed to compare the effects of the treatment on proliferation in two mouse 
models recapitulating the features of human PDAC, namely the KC Pten and KPC. 
TGFβ inhibitor study characterised the acute impact the administered TGFβ 
antibody has on proliferation in KPC mice in addition and as opposed to 
gemcitabine monotherapy, which is currently considered a golden standard in 
the treatment of pancreatic cancer.  This study utilized gamma counting, 
autoradiography and Ki67 immunohistochemistry (IHC). 
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1 Introduction 
1.1 NEMA Standard as an Assessment of PET 
From the end-user’s point of view, the most important qualities of the PET 
scanner are:  
1) stability and reliability reflected in high up-time and repeatability of the 
measurements; 
2)  technical parameters sufficient to detect the features of interest in the 
scanned subject; 
3) quantifiability of the acquired images allowing for accurate 
characterisation and differentiation of the observed phenomena and 
processes. 
Naturally, those criteria cover a variety of technical aspects and, depending on 
the potential scanning subject (e.g. human, small-animal, etc.) can be, to a 
different degree, satisfied by many commercially available and research 
instruments. Each of these devices utilises distinct technology and form factor, 
resulting in the particular performance characteristics. The question arises as to 
how one can describe the basic attributes of the PET scanner and its ability to 
produce an image that would: a) be applicable to all scanner geometries and 
detector technologies, and b) assess raw hardware capability without corrections 
and post-processing enhancements. In other words, the challenge is to devise a 
set of tests that would be applicable to all scanners and allow for their fair 
comparison.  
This need was addressed by a consortium of manufacturers and researchers, who 
under the umbrella of the National Electrical Manufacturer’s Association (NEMA) 
prepared a standard known as NU2, which was first issued in 1994 and updated 
in 2001, 2007 and lately in 2012. NU2 describes a set of standardised tests that 
aim at assessing a few basic parameters of the PET scanner, which depend 
mostly upon the employed hardware solutions. These parameters are: 
21 
 
 
 spatial resolution, 
 sensitivity of the scanner, 
 count-rate performance, and 
 image quality. 
NU2 is useful to assess most of clinical PET scanners.  However, it cannot be 
applied, at least not without some adaptations, to a sub-class of PET devices 
called small-animal (micro) PET scanners or Positron Emission Mammographs 
(Lawrence MacDonald, 2009; Luo et al., 2010). The main reasons for this are 
related much smaller fields of view of the scanners in question, which become 
apparent when one examines the sizes of the phantoms prescribed by the 
standard and the procedures described in, e.g. a spatial resolution test, which 
cannot be followed as stated for most of those scanners. For this reason 2008 
saw a publication of another NEMA standard, an adaptation of the 
aforementioned NU2 for this group of imaging equipment and called NU4. Since 
then it has been successfully used by manufacturers and users of small animal 
PET scanners and became widely acknowledged to the extent that NEMA NU4-
2008 tests:  
 became a standard way of reporting performance parameters of newly 
developed equipment; 
 lay down the foundation for acceptance testing for newly commissioned 
devices; 
 have become a tool for benchmarking various scanner technologies. 
It is, however, worth observing that the standard in its disclaimer states that its 
purpose is merely to provide guidelines for testing and not “to police or to 
enforce compliance with the contents of this document”. 
(National Electrical Manufacturers Association, 2008) Therefore, even though not 
every camera on the market was evaluated following the standard to the letter, 
NEMA NU4 has still been a tremendous help in comparing different devices and 
making purchasing decisions based on the testing results for many research 
centres. 
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1.2 Performance of Other Modalities 
1.2.1 NEMA Standards for Other Modalities 
Apart from NU4-2008, NEMA has published a few other standards covering 
molecular imaging. They are summarised in Table 1 below.  
Table 1 List of the NEMA Test Standards related to Molecular Imaging and X-
Ray devices 
Name Title of the Standard Status 
Type of 
Device 
Scope 
NU1-2012 
Performance Measurements of 
Gamma Cameras 
Active 
Gamma 
camera, 
SPECT 
Clinical 
NU2-2012 
Performance Measurements of 
Positron Emission Tomographs 
(PETs) 
Active PET Clinical 
NU3-2004 
Performance Measurements and 
Quality Control Guidelines for 
Non-Imaging Intraoperative 
Gamma Probes 
Active 
Gamma 
probe 
Clinical 
NU4-2008 
Performance Measurements of 
Small Animal Positron Emission 
Tomographs (PETs) 
Active PET 
Pre-
clinical 
XR10-1986 
(R1992, 
1998, 
2003) 
Measurement of the Maximum 
Symmetrical Radiation Field from 
a Rotating Anode X-Ray Tube 
Used for Medical Diagnosis 
Rescinded X-ray Clinical 
XR11-1993 
(R1999) 
Test Standard for the 
Determination of the Limiting 
Spatial Resolution of X-Ray Image 
Intensifier Systems 
Rescinded X-ray Clinical 
XR15-1991 
(R1996, 
2001) 
Test Standard for the 
Determination of the Visible 
Entrance Field Size of an X-Ray 
Image Intensifier (XRII) System 
Active X-ray Clinical 
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XR16-1991 
(R1996, 
2001) 
Test Standard for the 
Determination of the System 
Contrast Ratio (SCR) and the 
System Veiling Glare Index (SVGI) 
of an X-Ray Image Intensifier 
(XRII) System 
Active X-ray Clinical 
XR17-1993 
(R1999) 
Test Standard for the 
Measurement of the Image Signal 
Uniformity of an X-Ray Image 
Intensifier (XRII) System 
Rescinded X-ray Clinical 
XR18-1993 
(R1999) 
Test Standard for the 
Determination of the Radial 
Image Distortion of an X-Ray 
Image Intensifier (XRII) System 
Rescinded X-ray Clinical 
XR19-1993 
(R1999) 
Electrical, Thermal and Loading 
Characteristics of X-Ray Tubes 
Used for Medical Diagnosis 
Rescinded X-ray Clinical 
XR21-2000 
Characteristics of and Test 
Procedures for a Phantom to 
Benchmark Cardiac Fluoroscopic 
and Photographic Performance 
Rescinded X-ray Clinical 
XR22-2006 
Quality Control Manual Template 
for Manufacturers of Displays and 
Workstations Labelled for Final 
Interpretation in Full-Field Digital 
Mammography (FFDM) 
Active 
X-ray 
Mammo-
graph 
Clinical 
XR23-2006 
Quality Control Manual Template 
for Manufacturers of Hardcopy 
Output Devices Labelled for Final 
Interpretation in Full-Field Digital 
Mammography (FFDM) 
Active 
X-ray 
Mammo-
graph 
Clinical 
XR5-1992 
(R1999) 
Measurement of Dimensions and 
Properties of Focal Spots of 
Diagnostic X-Ray Tubes 
Rescinded X-Ray Clinical 
 
However, as of 2016, NEMA has not published a standard that would cover any 
modality within the realm of small-animal scanners other than PET. Works have 
started on pre-clinical gamma camera performance testing guidelines and it is 
expected that the new standard will be published within the next few years. In 
terms of X-Ray devices, out of 17 different standards (called “XR” standards) 
listed on the NEMA website (National Electrical Manufacturers Association, 
2015), 11 were rescinded. It is worth noting that the active standards cover 
quality control guidelines for mammography, intraoperative or interventional 
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(e.g. angiography) X-Ray equipment, but not performance evaluation like NU1, 
NU2, NU3 or NU4. 
1.2.2 Performance Testing 
Since there are no published guidelines for SPECT or CT testing, manufacturers 
and users tend to use custom protocols adapted from what was published for 
clinical devices. It should be no surprise that literature and published 
specifications list a wide variety of custom tests, which on most occasions can 
be reduced to common denominators. Kachelriess notes the most basic 
parameters of micro-CT scanners, which may not provide enough details for 
benchmarking, but allow at least a comparison between various imaging 
protocols. (Kachelriess, 2008) Those parameters are:  
 spatial resolution,  
 image noise, 
 dose given to subject. 
The latter is certainly of great importance in small-animal imaging. Boone, 
Valazquez and Cherry estimate typical dose received by a mouse scanned using 
micro-CT to be between 100 and 300 mGy, which is 10 times higher than doses 
delivered to human during an analogous scan. (Boone et al., 2004)  This is not 
lethal, although may be sufficient to alter biological pathways and immune 
response in an animal (Boyd et al., 2006), affecting experimental outcome. 
(Willekens et al., 2010) It is particularly important to limit the radiation 
exposure from CT imaging when conducting longitudinal studies involving this 
modality. A cumulative absorbed whole-body dose of 5 to 7.6 Gy (depending on 
the strain) is estimated to be lethal to mice (it is the LD50/30 dose, which means 
that within 30 days, half of the exposed population will die). (Funk et al., 2004; 
Willekens et al., 2010) But even smaller doses can cause an unintended, 
“therapeutic” effect on tumours in oncological studies. Therefore, it is vital to 
use imaging parameters that would provide sufficient image quality, but would 
limit the exposure to ionizing radiation. The dose received from a CT scan is 
proportional to the current on the lamp, but the proportionality changes with 
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the voltage on the X-ray lamp. (Kachelriess, 2008) It will also be higher if more 
projections are taken, which is usually a function of the scan duration.  
Certainly, the variety of phantoms and protocols used makes it impossible to 
compare performance of emerging micro-CT devices. It is another matter if an 
objective comparison is as crucial for those devices as it is for micro-PET or 
SPECT scanners. In dual or tri-modal scanners CT serves usually as a mean to 
provide an anatomical reference, which aids with an interpretation of the 
functional (PET or SPECT) information that it is being overlaid upon. Because the 
level of detail they provide is usually sufficient for dual-modality imaging, the 
technology they use is not a focus of major improvements and can be considered 
mature, unlike the realm of small animal PET or SPECT, which are still 
developing fields. Therefore, in case of micro-CT users often rely on the 
information provided by the manufacturer for the choice of the most suitable 
imaging parameters and the quality control protocols, which means they may 
vary greatly between different sites.  
 
1.3 Bruker Albira PET/SPECT/CT 
1.3.1 Landscape of Pre-clinical Tri-modal (PET/SPEC/CT) 
Scanners 
Albira (Bruker Biospin Corp., Billerica, MA, USA) is one of few commercial tri-
modal, PET/SPECT/CT small-animal platforms. It is a modular device, which 
means it can be bought as a stand-alone PET, SPECT or CT, as a dual-modality or 
tri-modal system. Furthermore, PET is available in 1, 2 or 3-ring configuration 
and SPECT can use two models of gamma camera. The image of a two-ring Albira 
PET/SPECT/CT is shown on Figure 1. The features of all of those sub-systems are 
provided in Section 1.3.2. Multi-modal scanning in Albira is facilitated by 
sequential scanning with an imaging bed moving between PET and SPECT/CT 
gantries. Because of this setup, i.e. physical separation of those two gantries, it 
is not possible to select PET and SPECT acquisition protocols as part of the same 
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study. Radionuclide imaging is always performed first with CT (if selected) being 
performed as second.  
Some of the following text and figures in the reminder of Introduction come 
from my review on the evaluation of the Albira PET system using the NEMA NU4-
2008 standard. (Pajak et al., 2016) 
1.3.2 Albira Features 
 PET 
Most small animal PET scanners use discreet crystal detector technologies, which 
utilize an array of crystals in a detector block. A unique feature of the Albira 
PET scanner is that it implements continuous lutetium yttrium orthosilicate 
(LYSO) crystals. Each crystal has a shape of a10 mm- thick, truncated pyramid 
with 50×50 mm2 base and 40×40 mm2 top. Behind the crystal lies a position-
sensitive photomultiplier (PS-PMT, H8500 Hammatsu) and electronics using Anger 
logic to provide depth-of-interaction (DOI) information for each detected 
annihilation photon. (Balcerzyk et al., 2009) Each crystal is painted black to 
prevent internal reflection and every detector is covered with tungsten. 
Together such an assembly constitutes a single detector block. 
Eight detectors form a ring and up to three rings can be stacked next to each 
other. An interesting feature of the two- or three-ring configuration is  
the 14.4 mm gap between the rings (shown on Figure 2), which is the result of 
the crystal shape.  
The geometry of two-ring Albira PET system is shown on Figure 3.  
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Figure 1 (a) A two-ring Bruker Albira PET/SPECT/CT, (b) an animal imaging 
bed, (c) inside of the scanner (*) showing the stationary PET module and 
gamma cameras on the rotating SPECT gantry (**). 
 
 
Figure 2 Side view of the two adjacent rings in Albira PET emphasising the 
gap between the front of the detector crystals and the relevant dimensions 
given in mm. The green line indicates the full axial field of view and the 
short red lines indicate the axial positions at which spatial resolution 
measurements are taken. The red triangles mark the centre of each crystal. 
(Pajak et al., 2016) 
 
(a) (b) 
(c) 
** 
* 
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Figure 3 Schematic diagram showing 2-ring Albira PET with octagonal 
detector arrangement in each ring and the gap between the rings. Blue dots 
show the measurement points for spatial resolution in NEMA NU4 test. (Pajak 
et al., 2016) 
The distance between the faces of two crystals lying opposite each other is 
121.5 mm, but the physical aperture is 105 mm due to the tungsten shielding 
around the detectors. (Sanchez et al., 2012) Coincidences are detected in 1-to-3 
mode, which means that for example detector 0 may detect coincidence in pair 
with detectors 3, 4 or 5 in ring 1 or 11, 12, 13 in ring 2 or 19, 20 and 21 in  
a 3-ring configuration. This arrangement provides 80×80 mm2 trans-axial field of 
view (FOV). The axial FOV depends on the number of rings and can be 40 mm 
(one ring), 94.4 mm (two rings) or 148.8 mm (three rings).  
The timing window for detecting coincidences is set to 5 ns. The energy window 
for accepted events is pre-defined by the user in Albira software (Albira Manager 
tool). It is set as a percentage of the annihilation photon energy, 511 keV.  
30% energy window (358-664 keV) is recommended by the manufacturer for the 
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routine animal imaging, but a 50% energy window (255-767 keV) can also be used 
for the performance testing. Other values can also be set. 
The Albira PET has the ability to acquire images in static or dynamic studies.  
The imaging time (or a sequence of frames of certain duration) has to be  
pre-defined in a study protocol. As of the Albira software ver. 5.6, once a 
dynamic study is acquired using given frame durations, the only adjustment 
permitted is splitting longer acquisitions into a sequence of shorter ones. 
However, there is no option to merge shorter frames into longer.  
In general, the reconstruction software for the Albira is available in two 
configurations: as central processing unit (CPU)-powered or graphics processing 
unit (GPU)-aided one. The GPU-powered reconstruction software takes 
advantage of high-performance parallel computing algorithms and works on 
computer architectures featuring up to 8 graphics cards. This offers robustness 
and substantially shortens reconstruction times, allows smaller reconstructed 
voxel sizes and the CT-based attenuation correction (for PET). However, the 
price of the GPU-powered reconstruction workstations may mean that it will 
need to be subjected to a cost-benefit analysis prior purchase.  
The reconstruction software and workstation used in the following study is the 
CPU-based version. Its default reconstruction algorithm is the maximum 
likelihood expectation maximisation (MLEM) with 12 iterations and  
1×1×0.944 mm3 voxel size. The number of iterations can be freely changed by 
the user. Few other options, for example reconstructed FOV, the crystal 
pixellation and the voxel sizes of the reconstructed image are pre-set, but can 
be changed by the manufacturer at request. The smallest reconstructed voxel 
size a CPU-powered software option offers is 0.5×0.5×0.5 mm3 as opposed to 
0.3×0.3×0.3 mm3 available in the GPU-aided one.  
Albira PET is additionally capable of gating triggered by the signal from the 
cardiac or respiratory animal monitoring system.  
  
30 
 
 
 SPECT 
The Albira SPECT consists of two gamma cameras positioned 180° apart. Each 
camera consists of a 4 mm-thick monolithic caesium iodide CsI(Na) crystal 
behind which lies a position sensitive photo-multiplier tube (PS-PMT) and 
electronics. (Sanchez et al., 2013) At the moment there are two models of the 
available camera: S108 (100×100 mm2 crystal) and older and smaller S102 (50×50 
mm2). Both cameras come with a single pinhole collimator (SPH) and a multi 
pinhole collimator – S108 with 9 pinholes and S102 with 5 pinholes all of which 
are made of tungsten and need to be changed manually. According to 
manufacturer specification, at  
a140 keV photo-peak the energy discrimination is 14%, however, the energy 
ranges differ and are 30 to 400 keV for S108 and 40 to 250 keV for S102. 
Depending on their proximity, both cameras provide a variable FOV (axial and 
trans-axial), S108 30 to140 mm (pre-set values of 25, 50, 80 and 120 mm) (Spinks 
et al., 2014) and S102 20 to 80 mm (pre-set values of 20, 40, 60 and 80 mm). 
According to the manufacturer, the minimum resolution for S108 is 0.6 mm and 
for S102 is 0.8 mm. Cameras are mounted on a rotating gantry and during a scan 
obtain 60 projections over 180° or 360°, every 6°. The Albira SPECT comes 
equipped with special narrow bed for 20 mm FOV high-resolution imaging, 
additionally to the mouse and rat imaging beds used in the larger FOV imaging 
and utilised also in the PET and CT imaging. (Bruker BioSpin, 2012) 
 CT 
Albira CT consists of the x-ray lamp and detector that are rotating around the 
subject in the step-and-shoot mode. The x-ray source and detector are mounted 
on the same gantry as SPECT cameras. The nominal focal spot size of the 
generated x-ray beams is 35μm. (Bruker BioSpin, 2012) The potential difference 
between cathode and anode can be regulated between 4 and 50 kV with 35 kV 
and 45 kV being the two settings available to the end user as pre-sets. The 
current on the cathode can be adjusted between 0 and 1 mA and the pre-sets 
available to the user by default are 200μA and 400μA. The current on the lamp is 
responsible for the dose received by the subject being scanned. The current on 
31 
 
 
the lamp versus deep dose equivalent, as measured by the manufacturer, is 
shown in Figure 4. The dose is a function of the scan length, which is 
proportional to the number of projections.  
Deep-dose equivalent (DDE) 
Figure 4 Deep Dose Equivalent as a function of time in the Albira CT, 
courtesy of Carlos Correcher (Oncovision). 
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 Animal Handling and Monitoring 
The Albira comes with two types of animal imaging beds: for a mouse and for  
a rat, which differ in size, but otherwise look alike. Both are fit with a tooth-
bar, which allows for stretching an animal on the bed and have a nose cone, 
which feeds anaesthesia. Anaesthesia is fed through the tubing, which runs from 
the face mask, along the bed, imaging arm and then to the panel below imaging 
bed. From there it can be connected with a supply using a luer connector.  
The Albira is compatible with BIOPAC animal monitoring system (BIOPAC 
Systems, Inc., Goleta, CA, USA), which can be purchased with the scanner as an 
option. When purchased together, it connects with the Albira through a panel 
below the imaging arm. Exact implementation depends on the chosen modules. 
All versions of the Albira come also with a camera at the back of the imaging 
gantry, which feeds an image into the acquisition screen at the computer. This 
allows for the real-time observation of the animal during the study. 
 Software 
The Albira software suite contains acquisition and reconstructions software along 
with a supervision module used for regular quality checks. It has also the options 
to manage some study information the tracer used, researcher IDs, radionuclides 
and energy windows (PET and SPECT), and acquisition settings for the all three 
modalities.  
 List-mode format 
The Albira PET saves all the acquired data in list-mode (LM) format. Each LM file 
is binary and consists of 176-bit long header and then the list of all the 
registered events. Each event is described by the detector pair that registered it 
and a timestamp. In addition, the xy co-ordinates on each detector where the 
detection of the coincidence photon took place and its energy are given. When 
only one photon was detected within the timing window (set to 5 ns), the event 
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contains a “single flag”, which has a hex value of “0x100”. In this instance 
information from only one of the detectors is then available. The last value 
registered for each single or coincidence event is the “amount”, which is the 
floating-point value greater than 1 coming from the Q-factor correction. The 
latter is a correction, which compensates for the dead time, i.e. the loss of the 
linearity in the detector’s response as activity increases. It is calculated during 
the periodical calibration conducted by the vendor.  
An example of the data in list-mode format is shown in Figure 5 and was 
generated using lmViewer command-line utility supplied by the manufacturer.  
 
Figure 5 Example output of the lmViewer utility showing the format of Albira 
PET list-mode files 
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2 Aims and Objectives 
2.1 PET 
The aim of the following series of experiments is to evaluate Bruker Albira 2-ring 
PET according to NEMA NU4-2008 standard, which has not been previously 
conducted.  The following table (Table 2) summarises all parts of the NU4 
standard and their individual aims. 
Table 2 Summary of the aims of each part of NEMA NU4-2008 protocol. 
Part Aim 
Spatial 
resolution 
To assess the ability of the scanner to resolve very small 
features of the subject, i.e. what is the distance at which two 
points at the image can be distinguished from each other. 
Sensitivity 
To assess how sensitivity of the instrument changes along the 
scanner’s axis. 
Count-rate 
performance 
To assess the range of radioactivity doses within which the 
scanner’s response is linear and the value at which the 
detectors saturation occurs; estimation of the contribution to 
the measured signal coming from: true coincidence events, 
scattered events and random events. 
Image Quality 
To determine how well the instrument (and reconstruction 
software) deals with partial volume effect, level of noise and 
how well it resolves small structures under typical conditions 
occurring during small animal imaging. 
 
This assessment is meant to establish some of the basic hardware characteristics 
of the PET component of the Albira PET/SPECT/CT system and ascertain its 
suitability for mouse imaging.  
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2.2 CT 
Since no standard analogues to NEMA NU4 exist for micro-CT, the CT sub-system 
of the Albira is assessed in terms of its temporal stability, spatial resolution and 
contrast recovery using custom protocol. The goal is to establish the optimal 
settings for mouse imaging using data obtained by imaging mouse-like microCT 
phantom and verify those settings by conducting cadaver imaging. Additionally, 
the impact of the available reconstruction settings on the image quality is also 
investigated. 
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3 Methods 
3.1 NEMA NU4-2008 
Most of the methods described below were published before in (Pajak et al., 
2016). 
3.1.1 Spatial Resolution 
 Measurements 
A 22Na point source of nominal activity of 370 kBq (0.25 mm active sphere 
diameter, embedded in the middle of the acrylic cube 10 mm in each extent; 
Eckert & Ziegler Isotope Products, Valencia, CA, USA; shown schematically in 
Figure 6) was first positioned on the thin cardboard support at the axial and 
trans-axial centre of the FOV.  
 
Figure 6 Schematic picture showing the 22Na point-source used in spatial 
resolution and sensitivity measurements. (Pajak et al., 2016) 
60 second acquisitions were then taken at the radial offsets of: 0, 5, 10, 15, 20 
and 25 mm. The same procedure was repeated for a quarter of the axial FOV 
(23.6 mm from the axial centre of the FOV). The energy window was set to 50% 
(255-767 keV). 
All measurement points were marked as blue dots and are shown on Figure 3 in 
the Introduction above. 
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 Data processing and analysis 
Using a customised program (explained in more detail in section 3.1.5 
Computation) data were filtered to include only events within 30% energy 
window (i.e 358-664 keV). Then all data-points for both, 50% (255-767 keV) and 
30% energy windows were reconstructed using reconstruction software provided 
by the manufacturer (MLEM, 20 iterations, 0.5×0.5×0.5 mm3 voxel size, no 
corrections apart from built-in normalisation correction applied) and using STIR: 
Software for Tomographic Image Reconstruction (Thielemans et al., 2006). The 
algorithms used were single slice re-binning (SSRB) and 2D FBP (filtered back 
projection) with 0.33×0.33×0.33 mm3 voxel size and no corrections applied. It is 
worth noting that since the Albira’s list-mode format is proprietary, it could only 
be used in STIR after conversion into one of the supported formats, namely 
COMPET list-mode format. The appropriate patch interpreting COMPET list mode 
format in STIR was provided by Mr David Volgyes. Normalization to correct for 
variations in the detector efficiency was not applied for either energy window 
setting when using STIR. In order to analyse point spread functions (PSF) of the 
reconstructed images, AMIDE: Amide’s a Medical Imaging Data Examiner 
software (Loening & Gambhir, 2003) was used. Profiles were generated into: 
radial, tangential and axial directions and spatial resolution was measured as 
Full Width at Half Maximum (FWHM) and Full Width at Tenth Maximum (FWTM), 
which are defined as shown in Figure 7. 
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Figure 7 Definition of the Full Width at Half Maximum (FWHM) and Full Width 
at Tenth Maximum (FWTM). The peak denotes a point spread function (PSF) 
measured in a given image plane.  
 
3.1.2 Sensitivity 
 Measurements 
The same source as the one used in section 3.1.1 Spatial Resolution was placed 
on the thin cardboard support at the trans-axial centre of the FOV, at the edge 
of the axial FOV. A series of 60 second acquisitions were then taken (sufficient 
to acquire at least 104 of prompt counts). Imaging bed was used to move the 
source along the scanner’s axis in 1 mm steps from one edge of the axial field of 
view to the other.  Because the LYSO crystals, which are part of the detector 
assembly, are mildly radioactive, a background acquisition was acquired for 5 
minutes without any source inside the scanner in order to establish an intrinsic 
counts contribution from the crystals. 
 Data processing and analysis 
A customised program described in the section 3.1.5 Computation was used to 
decode the list mode files, create sinograms and to perform the required 
calculations on them. 
Half Maximum 
Tenth Maximum 
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All oblique lines of response were assigned to the appropriate axial slices using 
SSRB and sinograms (trans-axial bin size of 1 mm, slice distance 1 mm) were 
constructed. In every slice, for every angle in the sinogram, the pixel of the 
maximum intensity was found and all counts outside 10 mm from that pixel were 
set to 0. All the remaining counts in every slice of the sinogram were summed 
and all constructed sinograms added together. Finally, background counts 
masked in the same manner and normalised to the scan duration were 
subtracted from each slice.  
The system sensitivity Si (in cps per Bq) was computed as follows: 
 =  − ,	
 , 
where Ri denoted a count rate in the slice i, RB,i is a normalised background 
count rate in that slice (both in cps) and Acal is the source activity expressed in 
Bq. 
Considering the branching ratio of 22Na (fraction of the total radiation of the 
radionuclide that comes from positrons), which is 0.906, the absolute system 
sensitivity SA,i  in the slice i expressed as a percentage can be calculated as: 
, = 0.906 ×100, 
where Si is system sensitivity in the slice i. 
NEMA NU4 defines the mouse-region as the central 7 cm of the instrument’s 
axial FOV and the rat-region as the central 15 cm. Both lengths are meant to be 
the approximate sizes of the average rodent of these species. Therefore, the 
system and the absolute system sensitivity over the mouse-region were obtained 
by summing the slices Si and SA,i over the central 7 cm of the axial FOV, 
respectively. Because the total axial FOV od 2-ring Albira PET is less than 15 cm, 
the sensitivity (system and absolute) over the rat-region and the total sensitivity 
are equal, and were calculated by summing the counts over all slices.   
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3.1.3 Count-rate Performance 
Mouse Phantom 
The mouse-like phantom (Oncovision, Valencia, Spain) conformed to the NEMA 
NU4-2008 standard. The phantom was made of high density polyethylene (0.96 ± 
0.1 g/cm3) in the shape of a cylinder 70 ± 0.5 mm long and 25 ± 0.5 mm in 
diameter. A cylindrical hole of 3.2 mm diameter was drilled parallel to the 
central axis and at the radial distance of 10 mm to it. A schematic of the 
phantom is shown in Figure 8. 
 
 
Figure 8 Schematic figure showing phantoms used in count-rate performance 
part of the NEMA NU4 protocol, where a) denotes the body of the phantom, 
b) the hole drilled off-centre, and c) inserted radioactive line-source. (Pajak 
et al., 2016) 
Rat-like Phantom 
The dimensions of the rat-like phantom conformed to the NEMA NU4-2008 
standard. Briefly, the phantom was made of the same material as the mouse-like 
phantom and had a shape of cylinder 150 ± 0.5 mm long and 50 ± 0.5 mm in 
diameter. A cylindrical hole of 3.2 mm in diameter was drilled along the central 
axis at 17.5 mm radial offset. A schematic of the phantom is shown in Figure 8. 
 Measurements 
Mouse-like phantom 
The tubing of 2.5 mm external diameter was filled with 143 MBq of 18F over 60 
mm and threaded through the hole in the phantom, so the activity in the tubing 
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was aligned with the central 60 mm of the phantom. The phantom was 
positioned in the middle of the FOV and a series of 20 min acquisitions were 
taken over several half-lives until the activity decayed to 44.8 kBq.  
Rat-like phantom 
Tubing of 2.5 mm external diameter was filled with 233 MBq of 18F over 140 mm 
and threaded through the rat-like phantom (Oncovision, Valencia, Spain), so the 
activity in the tubing was aligned with the central 140 mm of the phantom. After 
positioning the phantom in the centre of the FOV, a series of 20 minute 
acquisitions was taken until the activity decayed to 115.6 kBq. 
 Data processing and analysis 
Acquisition files were read and processed using a customised program described 
in section 3.1.5 Computation. First, using SSRB the data were re-binned into a 
stack of 2D sinograms with 1 mm pixel size and slice distance of 1 mm. All 
sinograms were masked so that only the pixels located within a band 16 mm 
wider than the diameter of the phantom were kept and the rest set to 0. Then 
for every row in a sinogram, the pixel with the greatest intensity was identified 
as representing the centre of the line source. Projections were shifted so these 
pixels coincided with the centre of the projection. After this alignment, the sum 
projection was produced by summing all vertical pixels for every radial offset. 
The counts within the central 14 mm of the summed projections represented the 
sum of true, random and scattered events while the counts outside this strip are 
considered to contain only random and scattered events. Using linear 
interpolation, the pixel values at the borders of the above strip were calculated 
and their average multiplied by the number of pixels between them. The 
product of this multiplication was assumed to represent random and scattered 
events within the strip and by subtracting this from all events within the strip, 
the true counts were found. The total counts were found as a sum of all events 
in the sum projection. By subtracting the true counts from total counts, random 
and scattered events were calculated. 
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Event count-rates (R) for slice i of the acquisition j were calculated by dividing 
respective counts (C) by the duration of acquisition (Tacq,j): 
, =
,

,. 
Using acquisition taken at low activity, when count losses and random events 
were less than 1.0% of total events rate, scatter fraction (SF) was calculated as: 
 =  +  , 
where Rs is scattered- and Rt a true-event rate. 
Next, for slice i of acquisition j, the noise-equivalent-rate (RNEC,i.j) was computed 
as: 
 ,, =
,,!
"#",, , 
where RTOT,i,j denotes total event rate and Rt,i.j – true event rate for slice i of 
acquisition j. 
The true event rate (Rt,i,j) within the ± 7 mm band from the edge of the line 
source in every slice i of the acquisition j was computed as: 
,, =
$"#",, − %&,,'

, , 
where CTOT,i,j is the total number of coincidences in the slice i of the acquisition 
j, Cr+s,i,j – the number of random and scattered coincidence events in slice i of 
the acquisition j and Tacq,j - the duration of the acquisition j. 
Random event rate (Rr,i,j) was estimated as follows: 
%,, = "#",, − ( )*,+,,-./0+1, 
where RTOT,i,j is the total count-rate in the slice i of the acquisition j, Rt,i,j is the 
true coincidence events count-rate and SFi is the scattered events fraction. 
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Scattered event rate (Rs,i,j) was then calculated as: 
,,  "#",,  ,,  %,,  2,, 
where RTOT,i,j is a total coincidence event rate, Rt,i,j – rate of true events, Rr,i,j – 
rate of random events, Rint,i – intrinsic event rate derived from a scan of each 
phantom without  any activity in the tubing, and finally, i is a slice and j denotes 
an acquisition. 
Summing over all slices i for every acquisition j the scatter fraction (SFj) was 
calculated as: 
 = )3,,)*,,&)3,,	, 
where Rs,j is the rate of scattered events and Rt,j – true event rate. 
 
3.1.4 Image Quality 
 Measurements 
An image quality phantom (QRM Quality Assurance in Radiology and Medicine 
GmbH, Moherendorf, Germany) conformed to NEMA NU4-2008 specification. 
Briefly, it had a shape of a cylinder 50 mm long and 30 mm in diameter (as 
measured on the inside). It was made of polymethylmethacrylate and comprised 
of three parts: 
a) two cylindrical chambers having 1 mm-thick walls, each 15 mm in length, 
8 mm in diameter (internal dimensions), where one was filled with non-
radioactive water and the other contained air; 
b) a region containing five rods of: 5, 4, 3, 2 and 1 mm in diameter and 20 
mm long, which were filled with a radioactive solution; 
c) an uniformity region, 30 mm long, which contained a radioactive solution. 
A schematic of the phantom is shown in Figure 9. 
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Figure 9 Schematic picture showing NEMA NU4-2008 Image Quality phantom. 
Grey colour denotes the body of the phantom. White colour denotes the air-
filled (non-radioactive) chamber, blue the water-filled one and orange shows 
the water solution of the 18F. Green dashed lines indicate the regions and 
volumes of interest that were drawn within the image. (Pajak et al., 2016) 
 
The phantom was filled with 3.55 MBq of the solution of 18F, positioned centrally 
within the scanner’s FOV and imaged for 20 min.  
 Data processing and analysis 
The image was then reconstructed using Albira built-in reconstruction software 
with a 0.5×0.5×0.5 mm3 voxel size (the smallest available) and MLEM algorithm 
using variable number of iterations: from 2 to 100. Scatter, randoms and decay 
corrections were applied for every reconstruction. 
Using PMOD (PMOD Technologies Ltd., Zurich, Switzerland), a cylindrical volume 
of interest (VOI) (22.5 mm diameter and 10 mm length) was drawn over the 
centre of the homogenous region (as shown in green dashed line on Figure 9). 
Maximum, minimum, mean and standard deviation values were noted. Next, a 
cuboid VOI was drawn over the rods region, covering the slices over the central 
10 mm of their length. The image was cropped to this VOI and slices averaged to 
lower the noise. Circular ROIs, twice the physical size of each rod (Figure 9), 
45 
 
 
were drawn around them and the maximum intensity pixel within each ROI was 
identified. Using transverse co-ordinates of the maximum intensity pixels, line 
profiles through all rods were generated. The recovery coefficients (RC) for 
every rod were calculated as the ratio of the average counts (Meanlineprofile) for 
the rod along the generated profile to the average counts in the uniformity 
region (Meanuniform). The error on this value (%STDRC) was calculated as: 
%5) = 100 ∙ 78 529:%;<9=>?@29:%;<9A
!  8 5B2<;%C=>?@B2<;%CA
! 	 , 
where STDlineprofile and STDuniform refer to the standard deviations calculated for 
the line profile and the uniformity region, respectively. 
To estimate the accuracy of corrections, two cylindrical VOIs, each 4 mm in 
diameter (half of diameter of each chamber) and 7.5 mm long, were drawn 
centrally over air- and water-filled chambers (white and blue cylinders on Figure 
9). Spill-over ratios (SOR) were calculated as the ratio of the mean activity 
concentration within the VOIs to the mean counts within the uniformity region 
(Meanuniform): 
DE9% = F92GH*IJF92KL+MNJO, 
D% = F92H+JF92KL+MNJO. 
The errors on the SOR values, %STDwater and %STDair were calculated similarly to 
those for rods region: 
%5E9% = 100 ∙ 7 5E9%=>?@E9%
!  8 5B2<;%C=>?@B2<;%CA
! 	 , 
%5%  100 ∙ 7 5%=>?@%
!  8 5B2<;%C=>?@B2<;%CA
! 	 , 
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where STDuniform denotes the standard deviation within the uniformity region and 
STDwater, and STDair are the standard deviations within the water and air chamber 
VOI, respectively. 
 
3.1.5 Computation 
 Geometry transformation for sinogram generation 
The sensitivity and count-rate performance parts of the NEMA protocol required 
processing of the sinograms generated from data acquired containing only the 
coincidence events (single events were discounted). To build a sinogram the 
detector geometry had to be transformed into the scanner geometry (Figure 3) 
using a customised program.  
Section 1.3.2.6 List-mode format describes the structure of Albira PET list-
mode file. To describe the transformation between the detector and scanner 
geometry, capital letters XY denote the detector plane co-ordinates and small 
letters xyz denote the detector co-ordinates in the scanner space. As mentioned 
previously, each detector crystal is virtually pixelated into 300×300 grid. Hence, 
every event could be detected in one of 9 x 104 detection positions giving the 
virtual pixel a size of 0.1333×0.1333 mm2 (40 mm/300). In the list-mode file, 
this position is already corrected for the DOI.  
The initial step required loading the list-mode file using custom-written C++ 
application. First the header (initial 176 bytes) was read and then every 40 
bytes, which is the amount of memory used to save information about one 
coincidence event. Within each coincidence event the detector pair number 
assigned to that event was read. Table 3 lists all 48 detector pairs available in 2-
ring Albira PET.  
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Table 3 Summary of all available detector (det.) pairs for the 2-ring Albira 
PET 
Pair no 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Det. 1 0 1 2 3 0 0 1 1 2 2 3 4 8 9 10 11 
Det. 2 4 5 6 7 3 5 4 6 5 7 6 7 12 13 14 15 
Pair no 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
Det. 1 8 8 9 9 10 10 11 12 0 4 1 5 2 6 3 7 
Det. 2 11 13 12 14 13 15 14 15 12 8 13 9 14 10 15 11 
Pair no 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
Det. 1 0 0 3 5 1 1 4 6 2 2 5 7 3 6 4 7 
Det. 2 11 13 8 8 12 14 9 9 13 15 10 10 14 11 15 12 
Next, the two detectors involved in the coincidence event were considered 
separately. Taking into account the scanner geometry, the Y co-ordinate 
corresponded to z +/- half of the gap between the rings, depending which ring 
the detector was based in. The X co-ordinate on the other hand corresponded to 
x and y multiplied by the translational matrix that took into account fact that 
there are 8 detectors in each ring. The transition from one detector to the 
adjacent in the same ring required a rotation by 45˚. Using the fact that the 
300x300 detector matrix covers the physical area of 40×40 mm and using the 
transformation described above, the co-ordinates of a pair of events were 
determined. Determination of the co-ordinates of each pair of coincidence 
events allowed for determination of co-ordinates of a line of response (LOR). 
These LORs were used to construct the sinograms. 
Taking the centre of the axial and trans-axial FOV as a centre of the co-ordinate 
system, a sinogram was generated calculating for every LOR the radial distance 
from the centre of the co-ordinate system and the angle between the LOR and 
X-axis (0-180°). The Z co-ordinate, which is the slice the sinogram was assigned 
to, was found using SSRB.  
48 
 
 
 Sensitivity and count-rate performance calculations 
A customised program was needed to calculate sensitivity and count-rate 
performance results. For the sensitivity test, a text file was generated 
containing absolute system sensitivity for each slice corresponding to an axial 
co-ordinate. For the count-rate performance test a text file, which contained 
true, random, scatter events and scatter fraction for every acquisition file was 
obtained, which in turn related to decaying activity in the line source over time. 
In both cases the output files were then used to generate the required plots. 
3.2 Assessment of CT 
3.2.1 Measurements 
A schematic picture of micro-CT mouse-like phantom (Computerized Imaging 
Reference Systems Inc., Norfolk, Virginia, USA) is shown in Figure 10.  
 
Figure 10 A schematic picture describing the geometry and the dimensions of 
the micro-CT phantom. The exact densities and sizes of the individual rods 
are given in Table 4 Micro-CT phantom specification (courtesy of CIRS Inc.) 
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It was made of a blend of soft-tissue equivalent polymer and hydroxyapatite 
(HA), the mineral found in the teeth and bones of mammals. The phantom 
consisted of the body (polymer equivalent to muscle tissue) and 11 rods of 
different sizes and densities, described in Table 4. 
Table 4 Micro-CT phantom specification (courtesy of CIRS Inc.) 
Feature 
Tissue-like  
or HA Density 
[mg/cm3] 
Physical 
density 
[g/cm3] 
Electron 
density  
per cm3, 
×1023 
Relative 
electron 
density (RED) 
to water 
Size of the 
structure 
[mm] 
Body Muscle 1.063 3.483 1.043 60 × ∅ 27 
Rod 1 0 1.083 3.562 1.066 
20 × ∅ 2 
Rod 2 50 1.115 3.655 1.094 
Rod 3 100 1.148 3.747 1.122 
Rod 4 250 1.245 4.024 1.205 
Rod 5 500 1.408 4.486 1.343 
Rod 6 750 1.571 4.948 1.481 
Rod 7 0 1.083 3.562 1.066 
20 × ∅ 4 
Rod 8 50 1.115 3.655 1.094 
Rod 9 250 1.245 4.024 1.205 
Rod 10 750 1.571 4.948 1.481 
Rod 11 
Lung (low 
density, inhale) 
0.205 0.681 0.204 10 × ∅ 5 
 
The phantom was placed on the imaging bed and imaged according to the 
protocol summarised in Table 5. It consisted of all combinations of settings a 
user may choose before starting a CT scan: four different “quality” pre-sets, 
which define the number of acquired projections (“high resolution”, 1000 
projections; “best”, 600; “good”, 400; “standard”, 250), two different 
50 
 
 
settings for voltage (“high”, 45 kV and “low”, 35 kV) and two settings for 
lamp current (called also a “dose” in the Albira software, “high”, 400 μA and 
“low”, 200 μA) . All acquisitions within a protocol were taken sequentially as 
described in Table 5, with no breaks between the acquisitions. 
The protocol was repeated over three consecutive days. Every day then 16 
images were acquired, corresponding to one of the 16 combinations of possible 
CT settings. Therefore, 48 images were acquired in total. 
Table 5 Details of the CT protocol 
Frame no Quality No of projections Voltage [kV] Current [mA] 
1 
Standard 250 
35 0.2 
2 45 0.2 
3 35 0.4 
4 45 0.4 
5 
Good 400 
35 0.2 
6 45 0.2 
7 35 0.4 
8 45 0.4 
9 
Best 600 
35 0.2 
10 45 0.2 
11 35 0.4 
12 45 0.4 
13 
High 
resolution 
1000 
35 0.2 
14 45 0.2 
15 35 0.4 
16 45 0.4 
 
51 
 
 
A mouse cadaver was imaged using standard, best and high resolution quality 
and low voltage-high dose, high voltage-low dose and high voltage-high dose 
settings. 
3.2.2 Data Processing and Analysis 
Images were reconstructed using the Albira Reconstructor software and using 
FBP and three voxel sizes: 0.5×0.5×0.5 mm3 (image matrix of 128×128×128 px), 
0.25×0.25×0.25 mm3 (image matrix of 256×256×256 px) and 0.125×0.125×0.125 
mm3 (image matrix of 512×512×512 px) giving 144 images in total for the data 
acquired over three days. Each image was loaded into PMOD (PMOD Technologies 
Ltd., Zurich, Switzerland) and 12 VOIs drawn:  
 Ø16 mm × 12.5 mm within the body of the phantom, centrally, between 
the front and back rods, 
 Ø1 mm × 12.5 mm within rods 1-6, covering the central portion of the rod, 
 Ø2 mm × 12.5 mm within rods 7-10, positioned like above, 
 Ø2.5 mm × 10 mm within rod 11, positioned like above. 
All images were analysed using exactly the same VOIs and in the same positions. 
Statistics for each VOI were obtained using PMOD. Because the densities of rods 
1 and 7, 2 and 8, 4 and 9, and 6 and 10 are the same, the results for each pair 
were averaged. For every acquisition file each density was assigned the mean 
value of Hounsfield Unit (HU) measured over the three images reconstructed 
using different voxel sizes. All images were grouped first with respect to the day 
they were acquired and then with respect to distinct four current-voltage setting 
(i.e. 35 kV-0.2 mA, 45 kV-0.2 mA, 35 kV-0.4 mA and 45 kV-0.4 mA), regardless of 
how many projections were taken in order to acquire them (i.e. 250, 400, 600 or 
1000).  
Next, all high resolution images (i.e. acquired at “high resolution” setting and 
reconstructed using the smallest available voxel size, 0.125×0.125×0.125 mm3) 
were loaded into AMIDE software (Loening & Gambhir, 2003). At the transverse 
slice positioned mid-length of the front, 2 mm rods, middle of each rod was 
identified and line profile in the transverse direction was generated. Similarly to 
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3.1.1.2 Data processing and analysis section, FWHM was noted for each rod. 
This was done for the images acquired at the last day.  
Cadaver images were reconstructed similarly and analysed qualitatively with the 
attention paid to soft tissue features visible in the mouse’s abdominal cavity. 
 
3.3 Basic Animal Studies 
3.3.1 Dual-tracer Bone Imaging Study 
A conscious, healthy, 5-week-old male wild type mouse (22.7 g) was injected 
intravenously with 25.4 MBq of 99mTc-MDP (99mTc-Medronate) in 70 μl. After a 30 
min uptake period the animal was anaesthetised using a mixture of isoflurane 
and medical air (5% upon induction and 3% thereafter). The tail vein was 
cannulated and secured using tissue glue. The mouse was placed on the imaging 
bed and the SPECT acquisition was started (two beds, single-pinhole collimator, 
45 s per projection and 60 mm FOV). After the SPECT scan was finished, 3.90 
MBq of 18F-NaF was administered intravenously using the cannula and a 120 min 
dynamic PET scan was started (8×15 s, 2×30 s, 2×60 s, 1×120 s, 1×180 s, 10×5 
min, 6×10 min). A two bed CT scan followed immediately after the PET scan 
(400 projections, high current, low voltage). The timeline of the study is shown 
in Figure 11. The animal remained anaesthetised from the time of cannulation 
until the end of CT scan, i.e. for 4 hours and recovered without problems. 
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Figure 11 Timeline of the dual-radiotracer (99mTc-MDP and 18F-NaF) 
experiment: 1) i.v. dose of 99mTc-MDP; 2) uptake of 99mTc-MDP; 3) SPECT 
scan; 4) i.v. dose of 18F-NaF; 5) dynamic PET scan; 6) CT scan.  Animal was 
anesthetised from the beginning of SPECT scan until the end of CT scan (total 
of 4 hours) and recovered without problems. 
 
A second mouse study was performed on a healthy, 15-week-old male wild type 
mouse (37.4 g), using a similar protocol as above however the mouse was 
anaesthetised and cannulated prior to an i.v. injection of 54.84 MBq of 99mTc-
MDP and remained anaesthetised throughout the whole study. After 38 min 
uptake SPECT scan commenced (FOV 80, 22.5 min per bed, 2 beds). Dynamic PET 
acquisition started right after the SPECT scan and following an injection of 3.50 
MBq of 18F-NaF. Compared to previous study, the protocol was shortened to 90 
min (5×1 min, 5×3 min, 4×5 min, 5×10 min). Upon the end of PET scan, CT 
acquisition started (400 projections, high current, low voltage, 2 beds). 
3.3.2 Data Processing and Analysis 
In both cases: 
 the frames of dynamic PET scan were reconstructed using MLEM 
algorithm, 12 iterations, 0.6×0.6×0.8 mm3 voxel size, 130×130×100 px 
image matrix size; 
 SPECT image was reconstructed using OSEM algorithm, sub-set 4, 3 
iterations, 0.65×0.65×0.65 mm3 voxel size, 100×100×165 px image matrix 
size; 
 CT image was reconstructed using FBP algorithm, 0.25×0.25×0.25 mm3 
voxel size, 256×256×474 px image matrix size. 
Images were loaded into PMOD. For the first mouse, the last three frames of the 
PET scan were averaged. Then all images from the experiment were aligned 
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manually in the Fusion tool. Each image was rotated by 30° around the z-axis 
and the maximum intensity projections (MIPs) were generated. 
For the second mouse, the reconstructed dynamic PET image was loaded into 
the View tool in PMOD. Next, using automatic 3D hot pixel selection tool 
volumes of interests (VOIs) were drawn around major joints (patellae and 
clavicles), kidneys, skull and spinal column. Time-activity curves were 
generated. Additionally, MIPs were produced for different times through the PET 
scan. 
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4 Results 
4.1 NEMA Results for Albira PET 
Results in this section, including some of the text and figures, were published in 
(Pajak et al., 2016). 
4.1.1 Spatial Resolution 
Figure 12 presents example images of the point source acquired at the axial 
centre and at quarter of the axial field of view reconstructed using prescribed by 
the NEMA standard, SSRB and FBP algorithms. Using these, in the dual-ring 
configuration it was not possible to reconstruct images of a point source 
positioned along the axial centre of the FOV, because the centre of the FOV 
corresponds to the 14.4 mm gap between the two detection rings.  This 
highlights the challenges of 2D FBP when it’s applied to images acquired on PET 
systems implementing non-standard geometry.  For this reason, in this part of 
the evaluation MLEM reconstruction algorithm (default in the Albira’s 
reconstruction software) was used.  
The comparison between 30 and 50% energy window (measured as Full Width at 
Half Maximum, FWHM and Full Width at Tenth Maximum, FWTM – as defined in 
Figure 7) is shown in Figure 13. Spatial resolution as the function of radial offset 
for both energy windows remained nearly the same at both axial offsets and the 
differences between the values acquired at both energy windows were minimal. 
One can also observe that the spatial resolution was better at the quarter of the 
FOV, which is due to the proximity of the ring centre as opposed to the centre of 
the scanner, which overlaps with the gap between the rings. 
The best spatial resolution was measured at ¼ of the axial FOV, at 5 mm radial 
offset and was 1.55, 1.60 and 1.42 mm in radial, tangential and axial direction, 
respectively. 
The detailed spatial resolution results for both, SSRB+FBP and MLEM 
reconstruction methods for the 30% energy window are gathered in Table 6. This 
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table highlights the portion of results that cannot be derived following NEMA-
prescribed algorithms. 
 
 
Figure 12 Images of a point source acquired by the Albira at the 5 mm radial 
offset and: the centre (a) and quarter (b, c) of the axial field of view. All 
images are reconstructed using SSRB and FBP. a) The gap between the rings 
(denoted with a curly brace) is clearly visible on the coronal slice; b) at 
quarter of the axial field of view, the image of the point is visible; c) 
octagonal geometry causes streak artifacts on images reconstructed using 
FBP. 
(a) (b) 
(c) 
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Figure 13 Spatial resolutions obtained on the 2-ring Albira PET system shown 
as Full Width at Half or Tenth Maximum in radial, axial and tangential 
directions measured at the axial centre and quarter of the field of view (FOV) 
expressed as a function of radial offset. Graphs on the left represent 50% 
energy window (255-767 keV) and on the right, the 30% one (358-664 keV).  
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Table 6 Spatial resolution results using 20 iterations MLEM and FBP along with the pixel sizes and slice thicknesses used for both 
algorithms (Pajak et al., 2016) 
Reconstructed image pixel size (mm): 0.5 (MLEM) / 0.33 (FBP) 
Slice thickness (mm): 0.5 (MLEM) / 0.33 (FBP) 
At axial centre 
 0 mm 5 mm 10 mm 15 mm 20 mm 25 mm 
 Algorithm FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM FWHM FWTM 
Radial 
MLEM 1.72 3.13 1.68 3.06 1.93 3.52 2.24 4.08 2.58 4.71 2.81 5.12 
FBP N/A 
Tangential 
MLEM 1.70 3.10 1.75 3.19 1.63 2.97 1.68 3.07 1.74 3.17 1.95 3.55 
FBP N/A 
Axial 
MLEM 2.45 4.47 2.44 4.44 2.44 4.45 2.62 4.78 2.81 5.11 2.77 5.05 
FBP N/A 
At ¼ axial FOV from centre 
Radial 
MLEM 1.52 2.78 1.55 2.83 1.86 3.39 2.13 3.89 2.33 4.25 2.79 5.08 
FBP 1.78 3.24 1.92 3.50 2.59 4.73 5.14 9.37 6.81 12.42 7.91 14.41 
Tangential 
MLEM 1.69 3.07 1.60 2.91 1.58 2.8 1.65 3.01 1.66 3.02 1.95 3.55 
FBP 1.72 3.13 1.31 2.38 1.57 2.87 1.14 2.07 0.90 1.63 1.01 1.84 
Axial 
MLEM 1.45 2.64 1.42 2.59 1.48 2.69 1.55 2.83 1.52 2.78 1.62 2.96 
FBP 2.47 4.51 2.59 4.72 2.69 4.89 2.59 4.72 3.26 5.95 3.06 5.57 
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4.1.2 Sensitivity 
Figure 14 presents the axial absolute sensitivity profile for the 2-ring Albira PET for 
two energy windows: 50% (255-767 keV) and 30% (358-664 keV).  
 
Figure 14 Axial sensitivity profile of the 2-ring Albira PET scanner measured 
using two energy windows: 255-767 keV (50%) and 358-664 keV (30%).  
The peak absolute sensitivity was 5.30% and was measured in the axial centre of 
the scanner and at the wider, 50% energy window. Two smaller peaks can be seen 
marking the position of the middle of each ring on both sides of the central peak.  
Over the central 7 cm, which NEMA describes as a “mouse region”, the average 
absolute sensitivity was 3.0%. The “rat region” encompasses 15 cm, which is more 
than the axial FOV of 2-ring Albira PET and therefore the average absolute 
sensitivity over this region (and over the whole FOV) was 2.33%.  
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4.1.3 Count-rate Performance 
The scatter fraction for the mouse- and rat-like phantom was 9.9% and 22%, 
respectively. The overall count rate performance for both phantoms is presented 
on Figure 15. The maximum noise-equivalent count rate, RNEC, peak was 72 kcps and 
was measured at 205.4 kBq/ml for the mouse-like phantom. For rat-like phantom 
this value was equal to 42 kcps at 39.9 kBq/ml. 
 
Figure 15 Count-rate performance measured on the 2-ring Bruker Albira PET 
system using mouse- and rat-like phantoms filled with 18F. 
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4.1.4 Image Quality 
The results of the analysis of the image quality phantom study reconstructed with 
20 iterations of MLEM are given in  
Table 7 and Table 8.  
Table 7 Recovery Coefficients (RCs) for rods of different diameters measured 
using NEMA Image Quality phantom and the 2-ring Bruker Albira PET system 
(Pajak et al., 2016) 
Rod 
diameter 
Recovery  
co-efficient 
%STD 
1 mm 0.05 29.0 
2 mm 0.30 14.5 
3 mm 0.66 14.8 
4 mm 0.77 10.2 
5 mm 0.90 8.5 
 
Table 8 Accuracy of corrections calculated for the 2-ring Bruker Albira PET 
system for water- and air-filled chambers in the NEMA Image Quality phantom 
(Pajak et al., 2016) 
Region 
Spill-over 
ratio 
%STD 
Water-filled 
cylinder 
0.219 12.3 
Air-filled 
cylinder 
0.139 14.1 
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The recovery co-efficients (RCs) for the rods of different diameters ranged from 
0.05 to 0.90 and the %STD within the uniformity region was 4.9%. The relation 
between the reconstruction parameters (namely the number of iterations used) 
and RCs and spill-over ratios (SORs) is shown on Figure 16 and Figure 17, 
respectively. For rods with a diameter of 3 mm or more, the maximum RCs were 
reached at 16 iterations. The RC for the 2 mm rod reached a plateau of approx. 
0.45 at around 40 iterations, while for the 1 mm rod the RC slowly increased with 
increasing number of iterations and eventually approached 0.2 at 100 iterations. 
SORs for air- and water-filled chambers improved with increasing numbers of 
iterations, although the decrease was quicker for air-filled chamber. 12 iterations 
were required to achieve maximum RC for the biggest rod, while 20 iterations 
seem to give good balance between the RCs for all the rods and improved (i.e. 
lower) SORs. However, to maximise RCs for the two smallest rods and to improve 
SORs even further 40-60 iterations would be required. 
 
 
Figure 16 RCs determined for the 2-ring Albira PET for all rods as a function of 
the number of MLEM iterations. Marked are 12 and 20 iterations. 
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Figure 17 Accuracy of corrections for water- and air-filled chambers using the 
2-ring Bruker Albira PET as a function of the number of MLEM iterations. 
Marked are 12 and 20 iterations. 
 
4.2 CT Phantom Results 
4.2.1 Stability of the System and Basic Performance 
Figure 18 presents the results for three out of three out of four available voltage-
current settings, which share common characteristics 
By comparing data obtained over three subsequent days of acquisitions there was 
no difference between the Hounsfield units (HU) measured for images acquired 
using different number of projections between day 2 and day 3. On Day 1, the high 
voltage-low current setting showed significant variation between the HUs 
measured for different image quality settings. Over all three days, the low density 
(lung-like) structure within the phantom produced similar HU values for low 
voltage-high current and high voltage-low current settings (-579 HU and 555 HU, 
respectively averaged over three days), while the measured HU values for high 
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voltage-high current settings were about half of the low voltage-high current and 
high voltage-low current setting measurements (-291 HU). 
Another way of looking at system stability is to group the data by the voltage-
current settings combinations shown on Figure 19. The low voltage-low current (35 
kV - 0.2 mA) setting produced a negative contrast for bone structures leading to 
very high negative (over -10 000 HU) measured values. Hounsfield numbers for 
dense bone (rod 7, 750 mg/cc HA) for high voltage-low current (45 kV – 0.2 mA) 
setting were almost twice as high as low voltage-high current (35 kV – 0.4 mA) and 
high voltage-high current (45 kV – 0.4 mA) settings: 1790 HU vs. 1051 HU and 1139 
HU, respectively. This highlights that measurements for day 1 had the biggest 
variation not only within the certain voltage-current settings but also when using 
different reconstruction settings. The variation attributed to different 
reconstruction settings was more prominent as the density of the structure in the 
phantom increases, especially for the low current settings. 
Since the rods (1-6) were of a known diameter (2 mm), it is possible to determine 
the spatial resolution of the scanner. Figure 20 summarises the FWHM, as a 
measure of spatial resolution of the images acquired on day 3 of the experiment 
and reconstructed on high resolution FBP setting (0.125×0.125×0.125 mm3 voxel 
size). Rod 1, which contained no hydroxyapatite (HA) and rod 3, showed of the 
biggest variation of measured FWHM values. Rod 2 (50 mg/cc of HA) was hardly (if 
at all) distinguishable from the body of the phantom. In most cases, it was 
impossible to measure its apparent diameter and hence it is omitted from the 
summary below. The remaining rods had FWHM values of between 2.1 mm down to 
1.7 mm for rod 6. 
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Figure 18 Three lamp settings (low voltage-high current, high current-low voltage and high voltage-high current) over the period 
of three days. For each voltage-current combination, image of the phantom was acquired using different numbers of projections 
(250, 400, 600 or 1000). These are superimposed on the graph and are represented with points and lines, which colour 
corresponds to the voltage-current setting used. Each acquired image was reconstructed using high, medium and low FBP settings. 
Therefore, for each voltage-current-number of projection combination of settings, three measurements were obtained. This value 
is shown as individual points on the graphs. The error bars represent the standard error of the mean of this value.
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Figure 19 Summary of the results for all combinations of voltage and current 
settings for the data acquired over three consecutive days. Lines are colour 
coded for measurement taken on a different day. Every individual line 
represents the measurements for a different image quality setting and is an 
average of the measurements for the same setting that was reconstructed 
using three different FBP settings. An individual point represents a mean and 
standard error of the mean.  
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Figure 20 The spatial resolution measured as a Full Width at Half Maximum on transverse slice in the middle of the front rods 
region. The data were obtained using images acquired at day 3 and reconstructed using the smallest available voxel size 
0.125×0.125×0.125 mm3). The known physical diameter of rods 1-6 is 2 mm. The contrast between the body of the phantom and 
rod 2 was too poor for the rod to be clearly distinguished; therefore, is omitted in the above summary.
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4.2.2 Impact of Acquisition Settings on Image Quality 
Figure 21 shows a transverse slice through the middle of the region of the 
phantom (the same one in every case) containing rods 1-6 and rod 11 
reconstructed on the medium FBP settings (0.25×0.25×0.25 mm3 voxel size). 
Images were acquired on day 1 using all possible combinations of the available 
CT settings. 
The low voltage-low current setting (35 kV - 0.2 mA), including the high-
resolution setting (1000 projections), showed a strong beam hardening. On the 
other end, high voltage-high current setting (45 kV – 0.4 mA) also showed some 
beam hardening around rod 11, but even using the standard quality (250 
projections) setting one can delineate all the rods (although rod 2 was hardly 
distinguishable). The low voltage-high current and high voltage-low current 
settings produced similar images, however, the low voltage-high current resulted 
in better contrast between rods 1 and 3 (0 vs. 100 mg/cc HA). Three out of four 
quality settings (“standard”, “good” and “best”) for the low voltage-high 
current and high voltage-low current settings suffered nearly equally from ring 
artefacts visible around rod 3. This feature seemed to disappear on the high-
resolution setting. Out of all combinations, the low voltage-high current and high 
resolution setting produced the most uniform-looking body of the phantom with 
all rods (except for rod 2) clearly delineated.  
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Figure 21 Representative transverse slices through the region of the phantom 
containing rods 1-6 and 11. Each image was acquired using one of the 16 
available settings combinations and reconstructed using FBP and 
0.25×0.25×0.25 mm3 voxel size. The orientation of the rods on the slice is 
consistent with the one shown on Figure 10, i.e. rod 1 is positioned at the 
bottom-left part of the slice and the rods are numbered clockwise. Rod 11 is 
in the centre. The scale used is -30 to 300 HU. 
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4.2.3 Impact of Reconstruction Settings on Image Quality 
Figure 22 and Figure 23 present the summary of the investigation of how the 
chosen reconstruction settings impacted the apparent image quality. In both 
figures the images presented were acquired during day 3 of experiment. They 
both present all available voltage and current combinations and show the same 
transverse slice through the middle of rods 1-6 and 11 against three available 
FBP settings (i.e. different voxel sizes) used during the reconstruction. The 
difference between Figure 22 and Figure 23 is the image quality setting used, 
the former being acquired using high resolution setting (1000 projections) and 
the latter the standard quality (250 projections). The scale used is from -30 to 
300 HU. 
When comparing the images above it can be seen that there is hardly any 
difference in image quality whether using 250 or 1000 projections when 
reconstructing images using medium or high FBP settings. However, beam 
hardening was slightly less prominent when using a higher number of 
projections and to certain degree this image artefact gets compensated for 
when using high FBP settings at reconstruction. Again, the images acquired 
using the low voltage-high current settings produced images that were the 
most accurate representation of the phantom.  
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Figure 22 Images acquired using the high-resolution setting (1000 
projections) and four available combinations of current and voltage settings.  
Rows from top to bottom present the same transverse slice through rods 1-6 
and rod 11 reconstructed using: high, medium and low FBP settings 
corresponding to 0.125×0.125×0.125 mm3, 0.25×0.25×0.25 mm3 and 
0.5×0.5×0.5 mm3 voxel size, respectively. 
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Figure 23 Images acquired using the standard quality setting (250 
projections) and four available combinations of current and voltage settings.  
Rows from top to bottom present the same transverse slice through rods 1-6 
and rod 11 reconstructed using: high, medium and low FBP settings 
corresponding to 0.125×0.125×0.125 mm3, 0.25×0.25×0.25 mm3 and 
0.5×0.5×0.5 mm3 voxel size, respectively. 
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4.2.4 Example Animal Images 
Representative images of a cadaver acquired using the best quality setting (600 
projections) using either high current (0.4 mA) and low voltage (35 kV), high 
current and high voltage (45 kV) or low current and high voltage are shown in 
Figure 24, Figure 25 and Figure 26, respectively. The data were reconstructed 
using the three FBP settings (0.5×0.5×0.5 mm3, 0.25×0.25×0.25 mm3 and 
0.125×0.125×0.125 mm3 voxel sizes), from top to bottom of the image, 
respectively. The display window was set to -30 to 300 HU to show soft tissue as 
well as bone structures. 
There was little difference between high and medium FBP setting 
(0.125×0.125×0.125 mm3 vs. 0.25×0.25×0.25 mm3 voxel size). Furthermore, low 
voltage-high current setting produced the best representation of the soft tissue 
out of the three settings presented, although delineation of different organs was 
not possible in most cases. 
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Figure 24 Representative image of a cadaver acquired using the Best quality 
setting (600 projections), the high current (0.4 mA) and low voltage (35 kV) 
setting and reconstructed using 3 different FBP settings. The display window 
was set from -30 to 300 HU, so soft tissue is visible. The images in columns 
from left to right show: transvers, sagittal and coronal slices and the last 
column shows maximum intensity projection (MIP). 
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Figure 25 Representative image of a cadaver acquired using the Best quality 
setting (600 projections), high current (0.4 mA) and high voltage (45 kV) 
setting and reconstructed using 3 different FBP settings. The display window 
was set from -30 to 300 HU. The images in columns from left to right show: 
transverse, sagittal and coronal slices and the last column shows maximum 
intensity projection (MIP). 
 
76 
 
 
 
Figure 26 Representative image of a cadaver acquired using the Best quality 
setting (600 projections), low current (0.2 mA) and high voltage (45 kV) 
setting and reconstructed using 3 different FBP settings. The display window 
was set from -30 to 300 HU. The images in columns from left to right show: 
transvers, sagittal and coronal slices and the last column shows maximum 
intensity projection (MIP). 
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4.3 Basic Animal Studies 
The ability of the Albira scanner to perform a dual tracer imaging study is 
highlighted in Figure 27, showing the maximum intensity projection images for 
both PET and SPECT bone imaging modalities obtained from a mouse (conscious 
during 99mTc-MDP uptake period). The CT image provided anatomical co-
registration for the nuclear imaging modalities. PET images obtained at different 
time points of the dynamic scan are summarised in Figure 28, highlighting the 
ability to perform dynamic imaging and determination of the optimal imaging 
period for a given radiopharmaceutical. As an example, Figure 29 presents a 
time-activity curve for the 18F-NaF dynamic study of the second mouse. 
PET and SPECT images in Figure 27 demonstrated the similar retention of the 
18F-throughout the body, although the SPECT image appeared to show more 
vertebrae and ribs). Both images showed smaller joints in front and hind limbs. 
Additionally, the PET image showed the hip and mandibular joints and sternum 
with improved delineation than the SPECT image. When compared with the CT 
image, both the PET and SPECT images accurately represented the skeletal 
structure of the mouse. The three images are shown in a slightly different axial 
field of view and a small gap was seen in the SPECT image corresponding to the 
split between two separate acquisitions at two beds positions. This was the 
result of the inaccurate stitching during the reconstruction process, which was 
fixed in later releases of the manufacturer software. 
Both Figure 28 and Figure 29 show the accumulation of 18F-NaF and its wash-out 
over the period of the scan.  Maximum accumulation of the 18F-NaF in the skull 
and spine was seen at 30 minutes post injection. However, at 60 minutes the 
joints achieved a maximum retention of 18F-NaF, while the uptake in the kidneys 
was further reduced compared to that seen at 30 minutes. At 90 minutes there 
was still enough 18F-NaF within the skeleton to produce good quality image, i.e. 
allowing the distinction of all the major joints and skeletal structure. 
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Figure 27 Maximum Intensity Projection (MIP) in dual-radiotracer 
experiment; a) 99mTc-MDP, b) 18F-NaF PET (Pajak et al., 2016), c) CT 
generated for the first mouse. 
  
(a)                              (b)                         (c)     
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Figure 28 Summary of 90 min dynamic PET acquisition: Maximum Intensity 
Projection (MIP) following the intravenous injection with 3.50 MBq of 18F-NaF 
at t=0 min. 
 
 
Figure 29 Time-Activity Curves showing accumulation, retention and 
clearance of 18F during dynamic PET scan following the intravenous injection 
of 3.50 MBq of 18F-NaF at t=0. 
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5 Discussion 
5.1 Performance Evaluation of 2-ring Albira PET 
5.1.1 NEMA NU4-2008 Overview 
NEMA NU4-2008 states guidelines for assessing performance of small animal PET 
scanners. It is by no means the only way of conducting performance testing of 
such devices nor is it exhaustive. For example, the standard states four tests 
using phantoms and prescribing certain measurements and calculations, 
however, it does not specify that the scanner is tested by an actual animal 
imaging study, which is the ultimate verification of a scanner’s usability. Of 
course one could argue that the purpose of NEMA is to facilitate benchmarking of 
different technologies. Although articles reporting NEMA results for new devices 
provide great reference for other manufacturers competing in the same market 
sector, they are also read by potential customers.  Scanner users may need to 
decide which scanner they are going to choose and since they bear a significant 
cost, users need to commit to the technology that they will be using for the next 
5-10 years. In his article on Mediso USA’s blog (Muller, 2014), Muller points out 
that this group of readers is more interested in the overall performance of the 
new device, while most review articles give for example only a peak sensitivity 
value, which most likely pertains a single point source positioned within the 
scanner’s FOV. NU4 standard also requires determination of values for average 
sensitivities over a mouse (central 7 cm) and rat (central 15 cm) FOV. These 
values are more useful when assessing how robust a scanner is. Muller warns also 
against review articles, which often contain out-of-date data. This may be due 
to the time-scales involved when publishing new papers, but in his view they 
“distort reality”. 
Although the NEMA standard does not explicitly require the acquisition of animal 
images by the system being tested, many articles reporting the performance of 
new scanners contain animal images. For an audience not familiar with the 
detailed performance parameters, they are more indicative of what can be 
achieved in the laboratory environment. Naturally a lot of hardware evaluation 
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research is conducted in engineering shops, where animal imaging is not 
feasible. It would be useful nonetheless to be able to compare animal images 
from different systems, which were acquired using standardised protocols.  
The existing NEMA NU4-2008 protocol may require some amendments within the 
near future. For example, in its sensitivity part it requires moving a point-source 
along the scanner axis. For scanners without automatic bed movement, this may 
be difficult to do as typically around a few dozen measurements need to be 
acquired every 0.5-2 mm step. Elhami and colleagues (Elhami et al., 2011) 
addressed this problem by comparing the measurements acquired using point-
source and using a line source and aluminium sleeves (which is the source used 
for assessing clinical devices according to NEMA NU2 standard). They found the 
difference to be within 0.9%, which indicates that a line source may be indeed 
be a more suitable phantom for sensitivity testing. 
NEMA NU4-2008 also requires the measurements of spatial resolution to be 
reconstructed using FBP. This, however, can be problematic when the 
manufacturer does not provide this algorithm within the standard software 
packages. For this reason, often users wanting to perform NEMA NU-4 testing 
resort to using a non-NEMA compliant reconstruction algorithm, such as iterative 
reconstruction methods (Herrmann et al., 2013; Spinks et al., 2014). In this 
case, results obtained using iterative reconstruction cannot be easily compared 
to those achieved using FBP reconstruction. On the other hand, FBP has some 
serious drawbacks, which can prevent one from obtaining any results at all at 
certain positions in the scanner. For example, in the 2-ring Albira PET the gap 
between the rings corresponds to the axial centre of the FOV. Using single slice 
re-binning and FBP it is impossible to reconstruct any images of the point source, 
regardless of their radial offset (Figure 12a). Yet using iterative reconstruction 
algorithms it is possible to reconstruct images from within the gap region. 
However, it also needs to be acknowledged that many of the built-in (iterative) 
algorithms by default apply corrections, which further improves the image. For 
these reasons caution should be taken when comparing values of spatial 
resolution reported for different machines. 
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5.1.2 2-ring Albira PET vs. other small-animal PETs and 1- and 
3-ring Albira PET 
Goertzen and colleagues published in 2012 a quite comprehensive overview of 
microPET devices and the NEMA NU4 results. (Goertzen et al., 2012) In 2014 
Kuntner and Stout (Kuntner & Stout, 2014) published another fairly exhaustive 
overview of small-animal PET covering technical parameters like those assessed 
by NEMA NU4 as well as some practical considerations regarding rodent imaging 
(e.g. anaesthesia, fasting, vitals monitoring) and PET images quantification. 
However, in terms of the performance characteristics it cites Goertzen et al. 
and adds Sofie Biosciences Genisys4 citing Herrmann and colleagues, (Herrmann 
et al., 2013) (although it does not include further NEMA evaluations of this 
system published by Gu et al. late in 2013 (Gu et al., 2013; Gu et al., 2011) and 
quotes results for the 1-ring Albira PET (Sanchez et al., 2012). Since then Spinks 
and colleagues published evaluation of the 3-ring Albira PET (Spinks et al., 
2014), although only part of those results was obtained following NEMA 
guidelines (i.e. sensitivity and count-rate performance results were calculated 
from reconstructed images and not sinograms and spatial resolution acquisitions 
were reconstructed using MLEM algorithm).  
Compared to 1-ring, the absolute sensitivity determined by this evaluation of the 
2-ring Albira PET system (5.3%) is over twice that reported by Sanchez et al. 
(2.5%). This is due to the difference in the axial FOV of the 2-ring Albira PET 
system (94.4 mm as opposed to 40 mm for the 1-ring variant). It could be 
therefore expected that the 3-ring version would achieve a similar step change 
in sensitivity of over 7%. However, Spinks et al. report only 6.3%. This 
underestimation could be due to the fact that their analysis was not conducted 
on raw sinograms, but images reconstructed using MLEM algorithm. Count-rate 
performances of all three variants cannot be directly compared since Spinks and 
his team did not analyse their data according to NEMA prescription. Despite this, 
the results for the 2-ring Albira PET system (scatter fraction of 9.9% and 22% for 
mouse- and rat-like phantoms, respectively) appear to be in line with those for 
1-ring (7.5% and 13%, for mouse- and rat-like phantoms, respectively). 
Furthermore, system saturation occurred at 205 kBq/ml and 39.9 kBq/ml for the 
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2-ring Albira PET system for mouse- and rat-like phantoms, respectively, while 
for 1-ring the same parameters were 370 kBq/ml and 42 kBq/ml, respectively. 
The lower saturation level observed in this assessment of the 2-ring system may 
be a result of larger field of view, while the signal-processing electronic 
remained the same for both systems. As an outcome, the 2 ring system needs to 
process more events than in the case of a shorter axial FOV, hence a lower 
saturation level. For both systems the usable range of activities reaches it upper 
limit at approx. 5-6 MBq. Interestingly, Spinks et al. claim the usable range of 
activities for their system to be up to 10 MBq. The difference may be explained 
since Spinks and colleagues performed their assessment on a scanner fitted with 
some more recent upgrades (with respect to the technology used in this 
investigated of the 2-ring Albira PET system. For example, new electronics will 
allow dead-time correction over broader range of radioactivities, thereby 
increasing the upper activity limit. Nonetheless, the 3-ring Albira PET system 
design allows for a wider acceptance angles and therefore more coincidences 
are registered, which will improve the scanner’s performance in every respect.  
One aspect that certainly differs between the 3-ring variant assessed by Spinks 
et al. and the 2-ring one discussed in this thesis is the image quality. The 3-ring 
Albira PET system utilised attenuation correction, which was unavailable for  
the 2-ring Albira PET system evaluated here nor was it used by Sanchez et al. for 
assessment of the 1-ring Albira PET. This affected the recovery co-efficients 
(RCs) and spill-over ratios (SORs) reported: RC for 5 mm rod was 95% for the  
3-ring PET as opposed to 90% for the 2-ring and 73% for the 1-ring versions; SORs 
for the 3-ring option were 0.20 for both, air- and water chambers, while for the 
2-ring PET they were 0.14 and 0.22, respectively and for the 1-ring version 0.30 
and 0.23, respectively. It is worth noting that the RC and SOR values for all three 
systems are not entirely comparable since the values for the 2-ring PET are 
reported for an image reconstructed using 20 iterations of MLEM. Even so, the 
differences among the results for the three versions of Albira PET are not as 
gross as one could expect looking at the effects of attenuation correction 
implemented in Siemens Inveon, which reduces SORs of both, water and air 
chambers to almost 0 and increases the RC for 1 mm rod to 21% (as opposed to 
5%, 3% and 2% for the 2-ring, 3-ring and 1-ring Albira PET, respectively). (Visser 
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et al., 2011) This may prove to be an opportunity for the future improvement of 
the reconstruction algorithms used by the Albira system. 
5.1.3 2-ring Albira PET vs. other tri-modal PET/SPECT/CT 
scanners 
The Albira is not the only tri-modal PET/SPECT/CT platform ever developed. 
There are three other available commercially: TriFoil Imaging Triumph (Aide et 
al., 2012; Prasad et al., 2011a; Prasad et al., 2010; Prasad et al., 2011b), 
Siemens Inveon (Bao et al., 2009; Kemp et al., 2009; Magota et al., 2011; Visser 
et al., 2009; Visser et al., 2011) and MILabs VECTor (Goorden et al., 2013). As of 
2015, the Inveon is no longer being manufactured. However, being in use at 
many research institutions, it remains probably the most popular to date. The 
VECTor platform is distinct among others since its imaging approach is based on 
the principles of SPECT imaging for both, single-photon and positron-emitting 
radionuclides. VECTor scanner contains of a common gantry made of three large 
stationary detectors common for the PET and SPECT imaging.  It is within this 
gantry that a cylindrical, clustered-pinhole (48 clusters of 4 pinholes) tungsten 
collimator is inserted. According to Goorden and colleagues (Goorden et al., 
2013) such design allows for simultaneous imaging of PET and SPECT 
radiopharmaceuticals. This could not be achieved in either Albira, Triumph or 
Siemens scanners, which all separate each of their modalities and allow for 
sequential imaging only. Yet, even though the simultaneous PET/SPECT imaging 
has its merits (visualisation of more than one molecular targets at the same 
time), it is worth noting that the sub-millimetre resolution for PET and SPECT, 
that authors claim, was not achieved following any standard protocol of 
performance testing, but a 1-hour scan of mini-Jaszczak phantom .This is a 
rather long imaging time compared to the 20 mins prescribed by NEMA standard 
in the image quality testing section. However, regardless of reported 
performance results, VECTor PET cannot be compared with PET sub-systems of 
aforementioned other commercial tri-modal platforms, because by using the 
collimator feature it is no longer a coincidence PET and cannot be fully 
quantitatively assessed.  
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The shared PET/SPECT detector gantry was recently reported for new animal 
PET/SPECT/CT system, a compact platform called Inliview-3000 (Wei et al., 
2015), which is not yet commercially available. Inliview-3000 features cone-
beam helical CT scanner, which has been by far used mostly in clinical machines. 
Additionally, the PET/SPECT detector ring is similar to the one used in Albira 
PET in the sense that it too uses octagonal detector arrangement in a ring, 
although unlike Albira, Inliview-3000 uses arrays of LYSO crystals (9720 crystals 
in total vs. 8 in Albira). The SPECT capability is achieved by the insertion of the 
rotating cylindrical tungsten multi-pinhole (50 elliptical holes) collimator 
between the detector ring and the imaging bed. In that sense Inliview-3000 
SPECT is somewhat similar to VECTor PET/SPECT. In terms of performance as 
prescribed by NEMA, results for the Inliview-3000 PET are in line with Albira and 
Triumph platforms – the only two remaining on the market. The system is 
described by Wei et al. as low-cost, which, if it remains the case, may change 
the landscape of small-animal PET/SPECT/CT scanners. 
5.1.4 Albira PET vs. MAMMI PET 
Since its publication virtually every new small-animal commercial scanner or 
even an upgrade over a previous version has been evaluated using NEMA NU4-
2008 guidelines. The standard has also found an application for special types of 
clinical scanners such as Positron Emission Mammographs (called also Mammi-
PET) for which NU2 was not appropriate given their unconventional geometry. 
(Luo et al., 2010) One such device of interest is the Oncovision MAMMI PET, 
which utliseses almost the same hardware as Albira (in fact, Albira PET was its 
predecessor) with the exception that instead of 8 detectors, it contains 12 in a 
single ring of detector. The MAMMI PET system requires the patient to lie on her 
abdomen so that the breast, hanging through the hole in the bed is positioned in 
the aperture of the scanner gantry below. Evaluation of such geometry required 
Soriano et al. (Soriano et al., 2013) to adapt NEMA standards NU2-2007 and NU4-
2008. Furthermore, the device assessed in their work was an improved, the 2-
ring version of MAMMI PET, which used also thicker LYSO crystals: 12 mm instead 
of 10 mm used in the Albira system or in the 1-ring MAMMI and, unlike 1-ring 
MAMMI, utilised DOI correction. This work is of even more interest since the 2-
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ring MAMMI, like 2-ring Albira suffers from the gap between the rings, which 
encompasses the centre of the axial FOV.  The reported sensitivity, even though 
twice than what was reported for the 1-ring MAMMI (Moliner et al., 2012), was 
3.1% as opposed to 5.3% for the 2-ring Albira. The difference may be a result of 
the geometry of the MAMMI scanner, which has a larger aperture than Albira (to 
allow space for a human rather than a rat or mouse and therefore has smaller 
acceptance angles for registered coincidences. It is also noteworthy that Soriano 
and colleagues measured better spatial resolution at the quarter of the axial 
FOV rather than in the centre: 1.6, 1.8, 1.9 mm at the centre vs. 1.5, 1.6 and 
1.7 mm at the quarter of the axial FOV in radial, tangential and axial directions, 
respectively. This is the same observation as was made in the 2-ring Albira PET, 
where in the quarter of the axial FOV spatial resolution is 1.5, 1.7, 1.5 mm as 
opposed to 1.7, 1.7, 2.5 mm in the centre in radial, tangential and axial 
directions, respectively. Furthermore, it can be expected that the spatial 
resolution results obtained could be further improved if NEMA would allow for a 
different choice of the axial position for spatial resolution measurement. In 
particular, if the measurements were made in the centre of the rings. As such, 
the current requirements of NEMA NU4 are sub-optimal for the scanners like the 
Albira PET or MAMMI PET.  
5.1.5 Albira PET Improvements 
Recently an application note was published (Gonzalez et al., 2015) detailing 
some new improvements to Albira PET design developed by Oncovision. Unlike 
previous upgrades that allowed faster electronics or better reconstruction 
algorithms, the new improvements will most likely fundamentally change the 
Albira PET system and its performance. The first improvement announced by 
Gonzalez et al. is a reduction of the gap between the scintillators, which as a 
consequence reduces the gap between the detectors within the ring to 0.5 mm. 
This should improve the image quality and spatial resolution by reducing the 
streak artifacts (Figure 12c) seen in an image taken of a point source placed 
within the gantry of the current 2-ring Albira PET system.  
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Another improvement will be the shape of the scintillator crystals, which will 
still have 50×50 mm base, but the top of the crystal will increase from the 
current 40×40 mm to 48×48 mm. There will also be a major change to the 
photomultipliers used. Currently, the Albira PET system implements multi-anode 
position-sensitive photo-multiplier tubes (MA-PS-PMT). The new technology 
utilises silicon photomultiplier (SiPMs) photosensors along the monolithic 
scintillators (LYSO crystals). The latter are a feature of all the former 
generations of Albira PET, but the new detectors are more compact and 
compatible with simultaneous PET-MR or in-line CT. The application note 
stipulates the new system (part of the new Albira platform called Albira Si) to 
have more uniform spatial resolution within the range of 1 to 1.2 mm. Sensitivity 
should also increase from about 9% to almost 12%. (Bruker BioSpin, 2014) 
 
5.2 Albira CT Performance and Quality Assurance 
Using a micro-CT mouse phantom, the basic stability of the CT system can be 
examined. The experiment conducted over three days revealed that during the 
first day there was a large difference between HU measured for the densest rods 
in the images acquired using a different number of projections. However, the 
variability between the measurements taken on the second and third day was 
minimal. This may be since on the first day the images were acquired within the 
first 30 mins after the system was powered on, while the system remained on for 
days 2 and 3. This would indicate significant relationship between the 
temperature of the lamp and quality of the acquired image. It would be 
therefore recommended that the Albira is on for at least an hour before any CT 
images are being acquired.  
The high current-high voltage setting underestimated the HU for lungs region 
(Figure 18). Whereas, the high current-low voltage and the low current-high 
voltage settings measured a value close to -600 HU for the lung region which 
agrees with the expected HU values for lungs (see  
Table 9). The best setting for small animal imaging would allow visualisation of 
the greatest difference between lungs and bone regions, and overall the highest 
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level of detail. The data acquired from the CT phantom clearly showed that low 
voltage-high current (35 kV – 0.4 mA) setting shows the biggest change in HU 
between the lung and bone densities.  
 
Table 9 Example Hounsfield Units (HU) for different types of tissue, air and 
water (Brant & Helms, 2007) 
Substance/tissue HU 
Air -1000 
Lung -800 to -400 
Adipose tissue -100 to -60 
Water 0 
Muscle 10 to 40 
Soft tissue 40 to 80 
Soft tissue (contrast agent) 100 to 300 
Bone 400 to 3000 
 
In terms of the amount of tissue detail visible, the number of acquired 
projections was found to be the parameter of the most significance. However, 
the absorbed dose is proportional to the duration of the scan and hence also the 
number of projections (Figure 4). And therefore, since some imaging studies may 
have a longitudinal design, which entails the repetitive exposure of the animal 
to the ionising radiation, the duration of the single scan becomes important. As 
Figure 21 shows, there is not much difference between “high resolution” and 
“best” settings, and therefore the shorter duration of the best quality setting 
may be considered more appropriate, especially when performing repeat 
imaging of the same animal. Furthermore, when the CT image is required to 
provide only a general frame of reference and smaller skeletal features are not 
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of importance, a lower quality may also be the more appropriate setting of 
choice.  
Some examples of the impact that reconstruction parameters have upon the 
image quality using “standard” and “high resolution” images of the CT mouse-
like phantom are shown in Figure 22 and Figure 23. The quality of the resulting 
images between “medium” and “high” FBP was very similar. The smaller the 
voxel size used during reconstruction, the larger the constructed image matrix, 
the larger the overall size of the image and the longer the reconstruction time. 
Unless CT is being used as stand-alone diagnostic tool, “medium” setting of FBP 
is probably the one that will satisfy most applications. Although the “low” 
reconstruction setting led to significant deterioration of the image quality, it 
may still be useful for a quick preview of the acquired data, but its usefulness 
beyond this is rather limited. 
The low current-low voltage setting showed strong beam hardening effects on all 
settings investigated and proves this acquisition to be unsuitable for animal 
imaging. On visual examination of the different reconstruction settings (Figure 
25 and Figure 26) the high current-low voltage showed the best image quality, 
albeit the contrast between the body of the phantom and 50 mg/cc rod is very 
poor. Analysis of the apparent quality of the images reconstructed using “high” 
and “medium” FBP settings led to the conclusion that the quality of the images 
reconstructed using 0.25×0.25×0.25 mm3 voxels is almost as good as of those 
reconstructed using 0.125×0.125×0.125 mm3 voxels. A cadaver was imaged using 
the high current-low voltage setting (Figure 25), which was identified as the 
preferred acquisition setting for small animal imaging studies.  The image 
allowed visualisation of the soft tissue within mouse however the soft tissue 
contrast is not sufficient to distinguish all the different organs. Different 
contrast agents may be considered to alleviate this problem. A good overview of 
CT contrast small animal imaging  was given by Wathen and colleagues. (Wathen 
et al., 2013). Injectable contrasts (e.g. Iomeprol 400, Omnipaque, gold 
nanoparticles, Aurovist, ExiTron nano 12000, Fenestra VC, Visipaque 320) can be 
used to show vasculature, liver or kidneys enhancement. In addition, the 
gastrointestinal tract can be visualised using ingestible contrasts (e.g. barium 
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sulphate). However, the use of contrast agents in small animal CT imaging has 
many limitations, namely: 
 the cost of many more sophisticated contrast agents (e.g. gold 
nanoparticles) can be high and may therefore be not feasible, 
 the use of contrast agents requires careful titration as they may have 
toxic effects upon an animal, 
 the use of contrast agents allows usually for enhancing an image only of a 
single organ, 
 dosing an animal with too high amounts of a contrast agent may lead to 
opaqueness of the affected organ not only for X-rays, but may also lead to 
scattering of the gamma-rays produced by single-photon emitting 
radionuclides or of the anti-parallel pairs of photons produced in the 
positron annihilation events, 
 in the experiments utilising nuclear imaging the use of contrast agent 
complicates imaging protocols leading to greater variability.  
5.3 PET/CT quality control 
The main objective of NEMA U4-2008 standard is the performance testing of 
small animal PET scanners. Apart from the benchmarking of the emerging 
technologies it is frequently followed in an acceptance testing of new scanners 
or in periodical (e.g. annual) quality control (QC) measurements. However, due 
to its complexity it is rather impractical for a weekly or day-to-day QC. Although 
to date no uniform QC standards were set for small animal PET scanners, clinical 
tomographs have been following such guidelines for years.  (Saha, 2010) 
The most basic test performed on PET is a uniformity test. It requires a 
transmission scan, which is acquired using long life positron emitter (e.g. 68Ge or 
137Cs) and generation of a sinogram from the gathered data. If there is a problem 
with any detector pair, it will appear on the sinogram as a streak. Furthermore, 
the uniformity test allows also for checking if the normalization works as 
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intended – any deviation will produce non-uniform sinogram. Unfortunately, 
generation of sinograms in the Albira requires writing custom computer code to 
process scanner’s list mode files, so any test requiring this form of 
reconstruction may prove to be impossible to follow through. Acquisition file 
could be reconstructed using the built-in iterative algorithms (MLEM or OSEM) in 
the provided software, but these reconstruction methods may obscure potential 
hardware problems. 
Another useful test, which may also be used to check the uniformity uses a 
phantom filled with positron-emitter (e.g. solution of 18F), which is then 
scanned. After the reconstruction (using the attenuation correction, where 
available) the image should be inspected for any non-uniformities. NEMA NU4 
covers such check in image quality part of the standard; however, the area of 
the phantom used is rather small. It would be more accurate to use a cylindrical 
phantom for this purpose (supplied by the Albira vendor) and image it in few 
different positions along the scanner axis.  
Above-described phantom can additionally be used to check for dead-time 
correction accuracy. Specifically, if filled with the solution of short-lived 
positron emitter like 11C or 18F it should be scanned repeatedly over few half-
lives of the isotope used. Resulting images, when reconstructed, on any selected 
VOI within the phantom should show activity concentration that follows the 
decay curve over time. Alternatively, measured activity should remain constant 
if decay correction was applied. If the measured activity in time differs from the 
theoretical value that can be easily calculated it may indicate a drift in the 
detector electronics or corruption of the dead time correction file. 
It may also be advisable to complete a dose calibration test, which requires a 
scan of a phantom (e.g. Jaszczak phantom) containing known activity 
concentration (or a range of different concentrations). Next these known values 
should be compared to those measured on the reconstructed image. The 
phantom used should have sufficient size to avoid partial volume effect (i.e. 
larger than approx. twice the spatial resolution of the scanner). 
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QC of the CT component requires similar approach. Namely, acquisition of an 
image phantom filled with water and/or air allows for verification of the HU 
values. Also, any dead-lines in the detector (non-responsive parts of the 
detector) will appear as streaks on the reconstructed image. In the clinical 
context, periodical dose measurement during the standard scan is performed to 
ensure patients safety; however, this is not a common practice in small animal 
CT QC.  
This work was focused upon performance evaluation of the Albira 2-ring PET 
based on the NEMA NU4-2008 standard and not on periodical QC measurements 
of any of its sub-systems. CT phantom was imaged to establish the most useful 
acquisition parameters in the mouse imaging studies and to test whether the CT 
component is thermally stable. It was established from the measurements that 
the scanner should be best powered on continuously to avoid quality 
fluctuations. This was not, however, a part of any QC protocol. 
5.4 Multi-modal Animal Studies 
Currently there are several commercial small animal single or dual-modality 
(combined with CT or MRI) dedicated PET or SPECT scanners. The power of the 
tri-modal platform, however, is in its flexibility and potential to utilise both 
nuclear imaging methods within one experiment. These dual radionuclide studies 
(PET and SPECT) studies take advantage of the fact that the photons emitted 
from the annihilation events occurring from PET radionuclides have greater 
energy (511 keV) than the photons emitted from SPECT radionuclides (e.g.140 
keV for 99mTc).  The order in which the SPECT and PET scans are completed is 
important for these dual radiotracer studies. To successfully complete a dual-
radiotracer imaging experiment, the SPECT radiopharmaceutical administration 
and scan must be conducted before administration of the PET 
radiopharmaceutical. This is to prevent the 511 keV photons from the PET 
radionuclide masking the photons being emitted from the SPECT radionuclide. In 
Figure 27 maximum intensity projections from a dual radionuclide imaging study 
are presented.  
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For all three modalities the image was rotated around the z-axis by 30° in order 
to show the uptake of the radiotracer in sternum and ribs. On the SPECT image a 
small gap within the middle of the image is visible.  It is thought that this may 
have been caused by the slightly inaccurate calibration of the instrument (wrong 
axial offset of the second bed scan) or error during the stitching of the images of 
individual beds into the final SPECT image. No corrections were applied in the 
SPECT image, nor was here any post-processing except for masking the bladder, 
which showed excretion of the radiopharmaceutical in the urine. All the major 
joints are visible, but the vertebrae cannot be distinguished. Scatter and 
randoms corrections were applied as part of the reconstruction of the PET 
image, so limited options exist in terms of improving image quality and the 
represented level of detail. The centre of the image, which corresponds to the 
gap between the detector rings, suffers from axial under-sampling, which in turn 
leads to blurry image of mouse’s spine. In comparison, the vertebrae in the tail 
are more distinguishable. This suggests that when imaging of structures 
approaching spatial resolution limit of the scanner (<1.7 mm) or smaller is 
required, the imaged subject should be positioned in the manner that structure 
of interest lays as close to the trans-axial centre and as close to the centre of 
the ring as possible. In any case the CT image can be used to visualise all the 
bones and the outline of the mouse’s body and bladder. 
The dynamic PET scan seen on Figure 28 and its complementary TACs (Figure 29) 
demonstrated that after 30 minutes the accumulation of 18F-NaF in most joints, 
vertebrae and skull is close to maximum.  This data suggests that a minimum 
uptake time of 30 minutes is required when imaging using 18F-NaF. The uptake of 
18F-NaF remained almost unchanged up to 90 minutes. Therefore, imaging mouse 
between 30 and 90 mins should yield optimal results. 
In future studies, if there was a region of interest the time-activity curves 
obtained in this study could be used to determine the optimal time to image 
that region. This highlights how when setting up new imaging protocols using a 
new radiopharmaceutical, dynamic scanning can provide information on the 
radiopharmaceutical pharmacokinetics and the optimal time for imaging. To 
further examine the kinetics of a radiotracer blood sampling would be needed to 
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establish a blood input function, which can serve as an input in kinetic 
modelling. However, for well-known radiopharmaceuticals (18F-FDG, 18F-NaF 
etc.) static imaging protocols can allow for serial and high through-output 
imaging. 
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Part II: Using 18F-FLT and Positron Emission 
Tomography in Monitoring Treatment 
Response in Murine Pancreatic Cancer 
Models
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6 Introduction 
6.1 Anatomy, Morphology and Role of the Pancreas 
The pancreas is an exocrine and endocrine gland, which forms part of the 
digestive system. On one hand, it secretes hormones like insulin, somatostatin, 
pancreatic polypeptide and glucagon, which control metabolism and blood sugar 
levels.  On the other, enzymes like trypsinogen, lipase, and amylase, among 
others, produced by the pancreas are indispensable for normal digestion, 
breaking down proteins, lipids and carbohydrates in stomach, duodenum and 
small intestine.  
The gross anatomy of the pancreas depends on the species in question. For 
example, the human pancreas is dense and compact. It can be divided into head, 
body and tail, while in mice parts of the pancreas are diffused and separated by 
a mesenteric fat.(Dintzis & Liggitt, 2012) In both cases the organ is encapsulated 
by the thin layer of connective tissue. 
Histological analysis of the pancreas allows for the distinction of important 
functional regions, identifiable regardless of species.(Dintzis & Liggitt, 2012; 
Dolenšek et al., 2015) These regions are: 
 Lobules, 
 Islets of Langerhans, 
 Blood vessels, 
 Lymph vessels, 
 Nerves ganglia, 
 Ducts. 
Each of the regions is associated with different type of cells, which form it. 
Those of particular interest in this work are: acinar cells (which form lobules), 
alpha, beta, delta and gamma cells (aggregated in the pancreatic islets) and 
ductal cells (pancreatic ducts). (Dintzis & Liggitt, 2012) 
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6.2 Differences between Human and Murine Pancreas 
The human pancreas is compact and its parts can be clearly distinguished. The 
pancreas of the mouse is, on the other hand, diffused and its parts cannot be 
clearly distinguished. At the histological level, the size of the lobules is relative 
to the size of the species, but this relationship does not hold for the islets. The 
ducts become larger for larger species. Mice have a common bile duct and 
pancreatic duct (or ducts), which drain to duodenum. In humans, common bile 
and pancreatic ducts first join at ampulla of Vater (major ampulla) and form a 
conduit, which then drains bile and pancreatic secretions into the duodenum. 
(Campbell & Verbeke, 2013) The islets of Langerhans vary in size and location 
within the murine pancreas and are about twice the size compared to human 
ones. Additionally, in mice the acinar cells have multiple nuclei, which is not the 
case in humans.  
6.3 Overview and Statistics for Pancreatic Cancer in UK 
6.3.1 Types of Pancreatic Cancer and Epidemiology 
Pancreatic cancer is one of the most lethal types of cancer. The chances of 
survival depend very much on the stage of the disease and its subtype. All 
pancreatic cancers can be divided into two general categories: endocrine and 
exocrine ones, where the latter account for over 95% of all cases. Pancreatic 
cancer can be broken down into the following sub-types (Pancreatic Cancer UK, 
2014): 
Exocrine 
 Pancreatic ductal adenocarcinoma (PDAC), 
 Solid pseudopapillary neoplasm, 
 Serous cystadenocarcinoma. 
 Acinar cell carcinoma, 
 Intraductal papillary mucinous neoplasm with invasive carcinoma (IPMN), 
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Endocrine 
 Neuroendocrine tumour (NET), 
 Somatostatinoma, 
 Mucinous cystic neoplasm with invasive carcinoma (MCN), 
 Insulinoma, 
 Glucagonoma, 
 Pancreatoblastoma, 
 Verner-Morrison syndrome (VIPoma). 
More than 60% of pancreatic tumours originate in the head of the pancreas and 
around 30% in its body and tail. 5% of pancreatic neoplasms grow in the whole 
organ.(Pancreatic Cancer UK, 2014) The most aggressive subtype, PDAC is 
diagnosed in more than 85% of all cases and is associated with the poorest 
survival: less than 5% in within the 5-year-period. Frustratingly, despite research 
effort, this survival rate has not changed in the last 40 years, which makes PDAC 
one of the deadliest types of cancer diagnosable. 
6.3.2 Risk Factors 
The exact aetiology of pancreatic cancer remains unknown; however, to date 
few main risk factors were identified: 
 tobacco smoking, 
 obesity (BMI over 35), 
 lack of physical activity, 
 ethnicity, 
 diabetes mellitus, 
 genetic predisposition, 
 age and gender, 
 chronic pancreatitis. 
Tobacco (and smokeless tobacco) smoking. Various studies suggest that tobacco 
smoking, including smokeless tobacco (Boffetta et al., 2005), increases the risk 
of pancreatic cancer between 20 to 100%. (Ekbom & Trichopoulos, 2008) 
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Smoking cessation reduces the risk over time, but it takes 20 years before it is 
comparable to the one of a person, who never smoked.  It is therefore the main 
avoidable risk factor.  
Obesity and lack of physical activity. Obesity also has been shown to increase 
such risk (de Gonzalez et al., 2003) and so does the lack of physical activity. (de 
Gonzalez et al., 2006)  
Diabetes. There is significant positive correlation between pancreatic carcinoma 
and diabetes mellitus type 2 (Adami et al., 1991; Noto et al., 2011; Zhang et al., 
2012).  
Familial history of pancreatic cancer. Having at least two diagnosed blood-
relatives increases the risk from 7 to 13 times, which points to genetic 
predispositions that may be inherited. (Ekbom & Trichopoulos, 2008; Fernandez 
et al., 1994; Ghadirian et al., 1991; Klein et al., 2004) 
Genetic mutations de novo. In over 90% of cases, however, the culprit mutations 
in oncogenes and tumour-suppressor genes are the result of de novo mutations 
acquired during an individual’s lifetime. (Ekbom & Trichopoulos, 2008; Petersen 
et al., 2006) 
Age, sex and ethnicity. Another factor showing strong positive correlation is age 
with most diagnosed cases being in persons over 65. Men seem to be slightly 
more susceptible than women and also African American origin predisposes to 
the disease more than other racial backgrounds. (Ekbom & Trichopoulos, 2008) 
Alcohol consumption. Excessive alcohol consumption (defined as 6 or more 
drinks per day) is also associated with increasing the risk by half. (Ekbom & 
Trichopoulos, 2008; Michaud et al., 2001) 
Pancreatitis. Chronic pancreatitis may nearly triple the risk of developing 
pancreatic cancer, but hereditary pancreatitis increases the risk of its onset by a 
factor of 70 by the age of 70 making it one of the most prominent risk factors in 
pancreatic adenocarcinoma. (AndrenSandberg et al., 1997; Ekbom & 
Trichopoulos, 2008) 
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6.3.3 Clinical Signs and Symptoms 
One of the reasons of high mortality in PDAC is its late diagnosis. Many patients 
do not experience symptoms in the early stages of the disease. Additionally, all 
initial symptoms can indicate conditions of gastrointestinal tract (e.g. 
pancreatitis, diabetes mellitus, gallbladder stones, jaundice), which are much 
more common. The clinical presentation may vary, depending on the origin of 
tumour (head, body or tail of the pancreas) and the type of the cancer, although 
most of the symptoms described below are common features of all pancreatic 
cancers, especially the exocrine cancers like PDAC.  
The most common symptom is an abdominal pain and/or upper back pain. This 
may indicate:  
 the cancer spread to the nerves surrounding pancreas,  
 an inflammation of the pancreas or surrounding organs,  
 an obstruction of the bile duct, stomach or duodenum by the growing 
tumour.  
Pancreatic tumours are solid, characterised by desmoplasia, which is suggested 
to be the source of their chemoresistance.(Whatcott et al., 2012)  They are 
unlikely to be palpable, although gallbladder may and in the advanced stages of 
metastatic disease umbilical nodule or nodules (Sister Mary Joseph nodule) may 
be felt. (Bai et al., 2012) 
Any of the above symptoms can in turn lead to nausea and vomiting, fever and 
shivering and, when the tumour blocks the bile duct, an obstructive jaundice. In 
the latter case, an excess of bilirubin in the blood causes the change of skin 
colour and whites of the eyes into yellow, itchy skin, dark urine and pale stools. 
An ascites (a build-up of fluids in the peritoneal cavity) can also occur in the 
advanced stages of pancreatic cancer. 
Due to the progressive loss of the function of the pancreas, there is 
underproduction of the endocrine digestion enzymes. This can lead to diarrhoea, 
steatorrhea (large, oily, pale, floating and foul-smelling stools indicating that 
the body is not digesting fats), and dyspepsia. The inability by the body to 
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properly digest and absorb nutrients eventually leads to weight loss. In the late 
stages of cancer development, cachexia usually occurs, which is characterised 
by a weight loss, loss of appetite, muscle atrophy and fatigue.  
A major symptom that can indicate a tumour growing in the pancreas is also 
diabetes. Sudden diabetes can cause: polydipsia (increased thirst), polyuria 
(increased urination), polyphagia (increased hunger), headaches, weight loss, 
fatigue, blurry vision, itchy skin or slowly healing wounds. However, there is also 
growing evidence that diabetes may be, in fact, a contributory factor to the 
development of cancer and not just its consequence. (de Gonzalez et al., 2003) 
6.3.4 Diagnosis and clinical classification 
All the aforementioned clinical signs are non-specific. Therefore, initially other 
possible diagnoses need to be excluded. Blood testing is conducted. Raised 
levels of conjugated bilirubin, alkaline phosphatase and γ-glutamyl 
transpeptidase in liver function tests usually indicate biliary duct blockage.(Carr-
Locke & Davies, 1980) Testing for a cancer marker CA19-9 (carbohydrate antigen 
19.9) is sometimes conducted. It has been shown that 85% of patients diagnosed 
with PDAC show elevated levels of CA19-9. Furthermore, there is a correlation 
between the level of this antigen and the stage of the disease. (Parikh et al., 
2014) 
Medical imaging is invaluable in determining the location of the tumour. This is 
done using one or more of the following imaging modalities: 
 Ultrasound (US), 
 Endoscopic Ultrasound (EUS), 
 Computed Tomography (CT), 
 Magnetic Resonance Imaging (MRI), 
 Magnetic Resonance Cholangiopancreatography (MRCP), 
 Positron Emission Tomography (PET). 
These techniques allow for a visualisation of the tumour and its location. 
However, in order to ascertain the exact type of cancer, an US-guided biopsy 
(usually by fine needle aspiration) is conducted. Pancreatic cancers can be 
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differentiated based on the morphological differences visible during the 
histopathological examination. To aid pathologists, medical residents and 
fellows the Johns Hopkins University School of Medicine compiled a 
comprehensive atlas of human pancreatic pathology. Providing gross anatomy 
and histological photographs it shows the features of 115 diagnostic entities. 
(Hruban et al., 2015) 
Based on the results of the aforementioned tests, the disease is classified using a 
two-tier system. First, a tumour is described using a TNM scoring system. “T” 
stands for “tumour” and describes the size of a tumour, with five possible 
values: from the smallest (Tis = carcinoma in situ) to the largest (T4). Lymph 
nodes involvement is considered (the “N” stage) and one of two discrete values: 
N0 or N1 is assigned (no lymph nodes involvement or cancer spread to lymph 
nodes, respectively). Metastatic spread (the “M” stage) is also either positive 
(M1) or negative (M0), which describes if the cancer spread beyond the pancreas 
or is still limited only to its primary organ. Based on the TNM staging, the cancer 
is classified as falling into one of four stages (from the least, stage 1 to the most 
severe, stage 4) of the disease advancement. 
6.3.5 Statistics for UK 
Cancer Research UK, a main cancer research and awareness charity in UK, on its 
website (Cancer Research UK, 2015a) summarised data provided by the statistics 
collecting authorities for all parts of Great Britain: 
 Office for National Statistics (Office for National Statistics, 2015),  
 Information Services Division (ISD) Scotland 
(Information Services Division Scotland, 2015), 
 Welsh Cancer Intelligence and Surveillance Unit 
(Welsh Cancer Intelligence and Surveillance Unit, 2015), and  
 Northern Ireland Cancer Registry (Northern Ireland Cancer Registry, 
2015). 
This summary spans from early 70s until 2012 and regards pancreatic cancer and 
its incidence, mortality and survival.  
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According to this publication, pancreatic cancer accounts for 3% of all new 
cancer cases, equally affecting men and women, and as of 2012 is the tenth 
most common cancer in UK with 8875 new cases (4453 men and 4422 women) 
diagnosed that year. This is slightly above the worldwide average of 2% (338,000 
new cases diagnosed in 2012), and in line with European statistics, which place 
pancreatic cancer as the eight the most common types of cancer (104,000 new 
cases in 2012, which is equal to 3%). The crude incidence rate per 100,000 
persons in the UK is 14 for males and females. 
Pancreatic cancer seems to strongly correlate with age. Only about 4% of new 
cases are diagnosed in patients below the age of 50 and almost half (47%) were 
diagnosed in persons aged 75 or over. Although the age-standardised ratio 
between men and women affected by this disease is 1:1, detailed analysis of the 
annual incidence rate distribution across the age groups for both genders shows 
that for ages 45 to 49 this ratio is 15:10. As of 2010 the lifetime risk of 
developing pancreatic cancer for men and women in UK is 1 in 73 and 1 in 74, 
respectively.  
Although, pancreatic cancer is rather infrequent compared to other cancer 
types; its mortality and survival data place it among the deadliest. Age-
standardised data for England and Wales for years 2010-2012 shows that almost 
21% of adults survive one year, but this percentage falls to only 3% when survival 
is measured over 5-years and to 1% in 10-year period. The survival rate shows 
strong correlation with age. Based on the data for England during 2007 to 2011, 
the 5-year survival rate for men is 14% among the population aged 15 to 49 and 
falls to only 2% for 80 to 99 year-olds. For women and for the same age groups 
the 5-year survival rates are 24% and 2%. There is then 10% difference between 
the 5-year survival rate of men and women in the under 50-age group. In Europe, 
the average 5-year survival rate is 5%, however, it ranges across different 
countries from 2% to 9%. Cancer Research UK suggests that this variation may be 
partially due to differences in data collection among the individual countries. 
The median survival for patients who have undergone surgical resection of the 
primary tumour is 11 to 20 months and their 5-year survival rate ranges from 7% 
to 25%. PDAC, however, is highly infiltrative, which means that it is frequently 
not easy to distinguish the margin of the disease (so-called R0- zero resection 
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margin beyond which the tissue is cancer-free). Therefore, although surgery is 
the most effective treatment for pancreatic cancer, most of the patients at the 
time of diagnosis have too advanced disease (either advanced locally or one that 
has frequently spread to other organs) or are too unwell to undergo the 
procedure. Therefore, patients with stage III (unresectable locally advanced 
disease) have 6- to 11-month median survival and stage IV (metastatic disease) 
only 2 to 6 months. 
Over the last three decades (1979-1981 to 2010-2012) in UK, the incidence of 
pancreatic cancer among men aged 25 to 49 decreased by 30%, but for men aged 
70 to 79 over the first two decades of that period decreased by 19%, and then 
rose by 8%. Among females over the age of 60, however, the incidence rate is on 
the rise and increased by 14% from the late 1970s. For women over 80 this rate 
has been increasing since late 1990s and has risen by 11%. For other age groups 
of men and women the rate has remained stable over the last thirty years. 
6.4 Genetic Background of Pancreatic Ductal 
Adenocarcinoma 
6.4.1 Mutated Genes and Pathways 
As with many other types of cancer, pancreatic cancer is driven by a variety of 
genetic alterations, which affect cell proliferation, apoptosis, regulation of the 
cell cycle and other signalling pathways. The disease initiation and progression 
seem to rely mainly on activation of mutated oncogenes and inactivation of 
tumour supressing genes, which can be attributed to somatic point mutations 
and allelic losses. (Simeone & Maitra, 2013) The former group mainly target 
KRAS2, a proto-oncogene that has been identified in over 90% cases of 
pancreatic neoplasms. The main genes in the latter group are: CDKN2/INK4, 
inactivation of which was found in around 90% of cases; Tp53, mutations in 
which are encountered in approximately 75% of analysed cases and which are 
associated with metastatic disease (Hingorani et al., 2005; Morton et al., 2010); 
and SMAD4/DPC4, which is deleted in 55% of the resected tumours. Other genes 
involved in this type of cancer are BRCA2, which is encounter in 19% of familial 
cases (Hingorani et al., 2005) and less than 10% of sporadic ones. MSH2 and 
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MLH1, genes responsible for the DNA repair, are mutated in less than 10% of 
cases. It seems, however, that the less frequently encountered mutated genes 
are being identified in rather rare types of pancreatic cancer and do not coexist 
with KRAS or Tp53 mutations, which are mainly seen in PDAC.  
Based on the analysis of 456 resected pancreatic tumours Bailey and colleagues 
in their recent work identified 32 genes which could be assigned to 10 distinct 
signalling and cell differentiation pathways, i.e.: 
 KRAS, 
 TGFβ, 
 WNT, 
 NOTCH, 
 ROBO/SLT, 
 G1/S transition, 
 SWI-SNF, 
 Chromatin modification, 
 DNA repair, 
 RNA processing. 
Furthermore, analysis of gene expression allowed them to propose a new 
classification of pancreatic cancer consisting of four subtypes: squamous, 
pancreatic progenitor, immunogenic and ADEX (aberrantly differentiated 
endocrine exocrine), which in their view may aid in the development of new 
therapeutic targets and agents. (Bailey et al., 2016) 
6.4.2 Mouse Models of Pancreatic Ductal Adenocarcinoma 
 Rationale for Using Murine Models 
Many therapeutic targets and drugs in cancer research are discovered at the in 
vitro stage using biochemical and cell-based assays. The most likely next step in 
drug discovery are in vivo trials involving the use of animal models. Without the 
in vivo experiments, it is impossible to predict the behaviour of the therapeutic 
agent in a living organism from the in vitro results alone. Yet, many drugs fail at 
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the in vivo stage. In such cases at best they show no effect on the subject. At 
worst, they have fatal effect or cause such severe side effects that no 
therapeutic benefits can outweigh them. If the results at the in vivo stage, 
however, are encouraging, pilot clinical trials can be scheduled.  
An animal genetically closest to a human is a monkey. However, the use of 
monkeys in research is expensive and poses many ethical concerns. However, 
other mammals also can prove viable alternative. The Mouse Sequencing 
Consortium reports that out of 4000 genes that have been studied in humans and 
in mice only 10 appear in either one or the other species. 
(Mouse Sequencing Consortium, 2010) The potential of using mouse models of 
human disease is not only plausible, but it is a reality. There are various types of 
mouse models of cancer. One of them is xenograft, where human cells are 
implanted into immune-compromised mice, subcutaneously or into an organ they 
were taken from. Such models can be useful in the initial screening of drugs 
cancer cells may be susceptible to (so-called personalized medicine), but are 
less useful for studying disease initiation and progression.  
Genetically modified mouse models (GEMMs) focus on genes, which are 
commonly found to be mutated in certain sub-types of cancer. Some of those 
models very well recapitulate features of human disease. Their other benefit is 
the lifespan of a mouse, which is much shorter than the one of human. Mouse 
gestation lasts only 3 weeks; it is therefore possible to test research hypothesis 
over few generations of mice reasonably quickly. Below two mouse models of 
PDAC are described. The clinical symptoms mice exhibit in both models are very 
similar, although on the molecular level there are differences in the pathways 
activated. 
 KPC 
Hingorani and colleagues proposed a mouse model of PDAC based on the 
endogenous expression of mutated KRAS and Tp53 genes. (Hingorani et al., 2005) 
This transgenic model uses the Cre-Lox system to conditionally express those 
genes in Pdx-1 expressing pancreatic progenitor cells. Hence, the model is 
known as KPC (KRAS; Tp53; Cre-Pdx-1).  
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KRAS is a proto onco-gene and its point mutations have been identified in over 
90% of all diagnosed cases of human PDAC. Heterozygous (homozygous 
expression is known to be lethal at the embryonic stage), endogenous expression 
of mutated KRAS (henceforth noted as KRASG12D) is responsible for the initiation 
of pancreatic intraephitilial neoplasia (PanINs), which are understood to be the 
progenitor lesions leading to pancreatic adenocarcinoma and are common in 
elderly human population. (Hruban et al., 2008) PanINs are classified by grades 
corresponding to the level to histological changes observed. From the least 
severe these are PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3, beyond which 
carcinoma in situ is diagnosed. (Hruban et al., 2001; Maitra & Hruban, 2008) 
Although KRASG12D by itself can develop into carcinoma and then into invasive 
metastatic disease, its progression is slower than when it is concomitant with 
the mutations (or deletions) of the tumour suppressor genes like Tp53 (e.g. 
Tp53R172H, which is an ortholog of the mutation identified in human disease). 
Inactivation of Tp53 is observed at PanIN-3 grade of pancreatic lesions and 
beyond - in adenocarcinoma (Hruban et al., 2001), and is identified in up to 75% 
of PDAC cases.  
 KC Pten 
Another mouse model resembling KPC uses the Pdx-1-Cre system to conditionally 
express heterozygous mutation of KRAS (KRASG12D) and biallelic deletion of the 
Pten gene (Ptenflox/flox) in pancreatic progenitor cells (Pdx-1). Like in the case of 
KPC model, mutant KRAS is understood to be the initiator of the neoplasms in 
pancreatic tissue. Pten, on the other hand is another well-known tumour 
suppressor gene. In terms of the disease progression, this model resembles KPC; 
however, due to different genetic background the signalling pathways driving 
the disease, mainly PI3K/AKT and MAPK pathways. (Chalhoub & Baker, 2009; Hill 
et al., 2010) 
 Disease Onset, Clinical Signs and Necropsy Findings in Mouse 
Models 
One of the first signs of the disease is subtle weight loss, which, as the disease 
progresses, turns eventually into cachexia. Abdominal distention can be 
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observed, which, shortly before the end of life, becomes haemorrhagic ascites. 
Biliary and small intestine obstruction can occur. Animals adopt a slightly 
hunched position protecting the abdomen. As the tumour burden increases it 
becomes less active and stops grooming. KPC mice show the first clinical signs of 
the disease as early as 10 weeks of age and their median survival rate is 5 
months. (Hingorani et al., 2005) KC Pten mice exhibit very similar clinical signs, 
but have even shorter median survival of 3.5 months. (Hill et al., 2010) 
Upon the necropsy the tumour presents itself as hard, fibrotic tissue. Sub-
millimetre metastases can be appreciated upon the inspection of liver, 
sometimes also the diaphragm and lymph nodes. The spleen is generally 
enlarged, frequently doubled in size. 
Thymic lymphoma and lung cancer are occasionally observed in this model. In 
such cases animal shows difficulty breathing. Those symptoms may coexist with, 
but usually precede signs of PDAC, and they, not the latter, ultimately lead to 
the animal’s demise. 
6.5 Current Treatment of Pancreatic Cancer 
The treatment of pancreatic cancer depends very much on the stage of the 
disease. Pancreatic neoplasms are classified as either locally advanced, locally 
advanced with lymph node involvement, or advanced with metastatic spread. 
Their localisation (head, body or the tail of the pancreas) and large blood vessels 
involvement are also factors considered when treatment plan is drawn.  
Treatments can be divided into potentially curative and palliative. The main 
types of treatment available are: 
 Tumour resection, 
 Ablative or embolization therapy, 
 Radiotherapy, 
 Chemotherapy, 
 Immunotherapy, 
 Chemoradiation therapy, 
 Palliative therapy. 
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Additionally, the treatments may be combined, e.g. chemotherapy can precede 
or follow tumour resection, which is called neoadjuvant or adjuvant therapy, 
respectively. 
6.5.1 Potentially Curative Resection 
The major requirement for potentially curative resection is disease advanced 
locally, without distant metastases, although metastases onto stomach and 
duodenum do not disqualify from the operation. Until recently involvement of 
the major blood vessels within and around a tumour was considered an absolute 
contraindication for resection, however, this is no longer the case due to 
improvement in surgical techniques. In any case, the medical state of the 
patient must be sufficiently good to allow for surgery, but due to late 
presentation, for many this is not an option. 
78% of PDAC tumours involve head, neck and uncinated process of the pancreas 
(Bond-Smith et al., 2012). For these pancreaticduodenectomy (Whipple 
procedure) may be used. It consists on removing the affected part of the 
pancreas along with part of the stomach, distal bile duct, and duodenum while 
restoring continuity of the gastrointestinal tract by connecting gallbladder, 
stomach and the remaining part of the pancreas to small intestine. However, 
within 30 days following the operation up to 40% of patients die due to 
complications like delayed gastric emptying or pancreatic insufficiency, among 
others. (Bond-Smith et al., 2012; Yang et al., 2005) 
Distal pancreatectomy may be performed when the tumour affects the body and 
tail of the pancreas. This procedure does not disturb the continuity of the 
gastrointestinal tract. Like pancreaticduodenectomy, it can be carried out 
laparoscopically. The most common complication is the leakage of the 
pancreatic fluid, which causes fistula formation at the resection margin. Hence, 
the morbidity for this operation can be as high as 28%.  
In both cases, patient survival improves, where disease-free resection margin 
can be achieved. In practice though, it is difficult to accomplish due to the 
highly infiltrative nature of PDAC cells and pancreatic morphology.  
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Total pancreatectomy means removing the entire pancreas and spleen. It is 
sometimes used where cancer affects the head or body of the pancreas and 
Whipple procedure cannot be performed. Patients after this type of surgery 
undergo pancreatic hormone and enzyme replacement therapy to combat the 
inevitable diabetes and lack of digestive enzymes formerly produced by the 
pancreas. Loss of the spleen makes patients prone to infections.  
Bleeding and infections are also a common risk during and after any of those 
kinds of surgery. 
 Neoadjuvant and Adjuvant Treatment 
Neodjuvant (before surgery) chemo- and chemoradiation therapy can reduce 
tumour burden and allow for the resection of borderline locally advanced 
disease. It improves also the chance for disease-free resection. 
Adjuvant (post-surgery) chemotherapy has been shown to improve patient’s 
survival as compared to chemoradiotherapy, which had the opposite effect as it 
was shown in the European Study Group for Pancreatic Cancer 1 trial. 
(Neoptolemos et al., 2004) 
6.5.2 Ablative or Embolization Therapy 
Tumours may also be destroyed using ablative or embolizing techniques.  
Small tumours (up to few centimetres in length) or proximal metastases may be 
destroyed using ablative treatments as described below. 
(American Cancer Society, 2016a) 
 Radiofrequency ablation (RFA) uses a thin probe, which is inserted into a 
tumour. High-energy radio waves emitted from the probe cause a 
temperature increase within a tumour and cancer cell destruction. 
 Microwave thermotherapy uses microwaves to heat up the tumour during 
procedure that is otherwise like RFA. 
 Cryoablation uses thin metal probe to deliver very cold gases to the 
tumour and freeze cancer cells.  
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 Irreversible electroporation (NanoKnife) utilizes electric current of high 
voltage, which is delivered through needles inserted into and around the 
tumour. (Pancreatic Cancer UK, 2015a) 
The procedures listed above may cause internal bleeding, infection or abdominal 
pain. 
Embolization requires a chemical substance to be injected into an artery 
delivering blood to the tumour to disrupt this blood flow and cause the cancer 
cells to die and may be used to treat unresectable pancreatic tumours and/or 
metastatic disease. 
 (Trans-)arterial embolization (TAE) requires a catheter to be inserted 
through a femoral artery, into hepatic artery and into celiac or splenic 
artery (Tanaka et al., 2012) (depending on the tumour position) and the 
artery providing blood flow to a tumour is occluded either by 
microparticles or a coil. 
 (Trans-arterial) chemoembolization (TACE) is performed similarly to TAE 
with the exception that either the beads used to occlude the target artery 
contain a chemotherapeutic drug or it is delivered using a catheter used 
for embolization. (Azizi et al., 2011) 
 Radioembolization combines radiation therapy with embolization 
treatment by introducing radioactive microspheres (filled with e.g. 90Y) 
into a target artery. Radiotherapy is hence delivered locally and the kind 
of radiation used (β-particles) ensures only the tissues within a small 
proximity from the microspheres position are destroyed. (Michl et al., 
2014) 
These procedures can cause side effects in the formation of blood clots, 
infection, fever, nausea or abdominal pain. (Bond-Smith et al., 2012) 
6.5.3 Radiation Therapy 
Most commonly high energy x-rays (external beam radiation) are used to treat 
pancreatic cancer, particularly in patients with unresectable locally advanced 
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tumours or whose health status makes surgical resection impossible. 
(Pancreatic Cancer UK, 2015b) 
6.5.4 Palliative Treatment 
Palliative treatment involves various approaches to manage symptoms, where 
the disease progressed beyond the point, where cancer remission can be 
achieved. (Bond-Smith et al., 2012) 
 Obstruction of duodenum or biliary tract is one of the most common 
problems that can be resolved by surgical or endoscopic stenting, bypass 
surgery or radiotherapy.  
 Exocrine insufficiency, which causes fat malabsorption can be 
counteracted by supplementing pancreatic enzymes like pancreatin.  
 Delayed gastric emptying can be managed by e.g. nasogastric drainage, 
pro-kinetic medication or nutritional supplementation. 
Unresectable tumours or distant metastases can be treated with radiotherapy or 
chemotherapy to prolong survival and lessen the pain. When the cancer reaches 
nerves leading to the pancreas it is possible to relieve the pain to the patient by 
cutting them or injecting with alcohol. (American Cancer Society, 2016b) 
Pharmacological pain management is also an option, with opioid medications like 
morphine being most commonly used. 
Immunotherapy using GV1001, a monoclonal antibodies and the telomerase 
vaccine is currently in clinical trial with the hope that it may prolong survival of 
patients with unresectable or metastatic disease. (Cancer Research UK, 2015b) 
6.5.5 Chemo- and Immunotherapy 
 Standard Treatment 
Below listed and briefly described are the most common chemotherapeutic drugs 
used clinically for the treatment of PDAC. 
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 Gemcitabine is a cytidine analogue, which by being incorporated into the 
DNA and RNA of the cancer cells can inhibit their proliferation, prevent 
their repair and in consequence induce apoptosis. It is considered a 
“golden standard” in the treatment of PDAC; in particular, in the 
adjuvant therapy and metastatic disease. (Alvarellos et al., 2014; Louvet 
et al., 2002) Oxaliplatin is platinum-based antineoplastic drug. Through 
its DNA-crosslinking properties it inhibits DNA synthesis and repair. It is 
used on its own or in combination with 5-FU, which is called FOLFOX. 
(Ehrsson et al., 2002) 
 Fluorouracil (5-FU) is a pyrimidine analogue and functions as another anti-
proliferative compound. It does so by interfering with the synthesis of 
thymidine via inhibition of the enzyme needed for its production, 
thymidylate synthase. It is highly toxic and may cause nerve damage. It is 
being used on its own or in combination with other drugs (e.g. as part of 
FOLFIRINOX). (Johnston & Kaye, 2001; Longley et al., 2003) Capecitabine 
is a pro-drug administered orally instead of intravenously, which via 
enzymatic action of dihydropyrimidine dehydrogenase is converted to 5-
FU. (Johnston & Kaye, 2001) 
 Paclitaxel interferes with cell division by targeting tubulin. It is an anti-
proliferative drug. However, it has severe side effects related to the 
solvent in which it is formulated. (Horwitz, 1992) Because of this problem 
alternative formulations were developed. Specifically, protein-bound 
paclitaxel (known as nab-paclitaxel) uses albumins as a form of paclitaxel 
delivery intravenously, which causes it to be better tolerated by patients. 
(Chen et al., 2015; Horwitz, 1992) 
 FOLFIRINOX is a combination of four drugs: folinic acid, which helps to 
reduce side effects of 5-FU; 5-FU; irinotecan, inhibitor of an enzyme 
responsible for the coiling of the DNA helix and its duplication; and 
oxaliplatin. It is used in particular in the treatment of the metastatic 
disease. (National Cancer Institute, 2011) 
 Immunotherapy 
The purpose of immunotherapy is the utilization of body’s natural defence 
mechanisms. This is done by introducing antigens specific to the tumour genetic 
114 
 
characteristics. The delivery routes of these vary and include whole cells, 
dendritic cells, DNA and T-cell receptor vaccines. (Gunturu et al., 2013; Loc et 
al., 2014) 
 Clinical Trials 
There are many clinical trials testing novel drugs or vaccines. Many trails 
compare the drugs currently used to treat patients with PDAC or their various 
combinations and treatment regimes. They address a broad palette of molecular 
pathways and targets, and all stages of tumour development and treatment. A 
recent in-depth overview of those was recently published by Garrido-Laguna and 
Hidalgo. (Garrido-Laguna & Hidalgo, 2015) 
6.6 TGFβ 
As mentioned above in the section 6.4.1 Mutated Genes and Pathways, one of 
the pathways affected during the development of PDAC is the TGFβ pathway. 
Transforming Growth Factor beta (TGFβ) is one of the cytokines, i.e. small 
proteins involved in cell signalling. In the context of cancer, it is an important 
part of inflammatory, proliferative, apoptotic and cell differentiation pathways.  
(Moustakas & Miyazawa, 2013) It has been shown that in early disease stages 
that TGFβ plays a tumour suppressive role by arresting proliferation and inducing 
apoptosis via its canonical, i.e. SMAD pathway. (Gaspar et al., 2007; Ten Dijke 
et al., 2002) SMAD proteins act as transcription factors and are activated by the 
TGFβ receptors. After forming complexes, they are translocated to cell nucleus, 
where they regulate gene activity (e.g. Tp53). However, at some point this 
changes and TGFβ starts driving cancer by inducing proliferation and aggregation 
of fibroblasts via its non-canonical pathways, most notably PI3K/AKT. (Ikushima 
& Miyazono, 2010) This pathway is activated by the tyrosine kinase Src. 
(Moustakas & Miyazawa, 2013) It can then either induce metastasis, angiogenesis 
and proliferation via AKT-mTOR activation, which in turn phosphorylates S6 
kinase, which is responsible for regulation of the protein synthesis. 
Alternatively, it can control proliferation via PI3K-Ras-Raf-MEK-MAPK pathway. 
(Khan et al., 2013; Rozengurt et al., 2014) Generally, in pancreatic cancer TGFβ 
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pathway eventually leads also to the formation of the tumour stroma – a typical 
feature of many types of pancreatic malignancies. (Apte et al., 2004)  
The exact mechanism and reason why TGFβ changes its role from tumour 
suppressor to driver is still speculative. (Akhurst & Derynck, 2001; Ikushima & 
Miyazono, 2010; Principe et al., 2014) However, it is understood that it has many 
functions and plays an important role in the epithelial to mesenchymal transition 
(EMT) (Kabashima et al., 2009), which is an important mechanism leading to 
cancer cell migration and metastasis. (Kalluri & Weinberg, 2009) Metastatic 
disease is one of the features of the KRAS and Tp53-driven PDAC. As such, this 
role of TGFβ has already been addressed in few early pre-clinical trials. 
(Neuzillet et al., 2015) It has also been targeted in few clinical trials for other 
kinds of cancer.  (Buijs et al., 2012) 
6.7 18F-FLT 
18F-Fluoro-L-thymidine (18F-FLT) is a thymidine analogue and is used to measure 
cellular proliferation. Indigenous thymidine is taken up by a cell and 
phosphorylated using thymidine kinase 1 (TK1). It can be then incorporated into 
the nuclear DNA. 18F-FLT relies on TK1 as well, but is trapped in the cell as 
radiolabelled phosphate compound. (Lamarca et al., 2016; Shields et al., 1998) 
It is therefore a surrogate a measurement of TK1 activity rather than 
proliferation itself. 
18F-FLT has been used in an imaging of pancreatic cancer in number of pre-
clinical and clinical studies and is often claimed to be superior in to 18F-FDG in 
the sense that it is more specific, although some studies show that it may have 
lower sensitivity than 18F-FDG. (Challapalli et al., 2012; Debebe et al., 2016; 
Herrmann et al., 2012; Lamarca et al., 2016; Lamarca et al., 2013; Quon et al., 
2008; Schober et al., 2013; Shreve, 1998; von Forstner et al., 2008) 
6.8 Research Questions 
The survival rates of patients presenting with PDAC are so low because diagnosis 
of the disease generally occurs too late for surgical intervention. Chemo- and/or 
radiotherapy also bring only marginal benefits in terms of survival, yet have 
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significant impact upon the quality of patient’s life. (Garrido-Laguna & Hidalgo, 
2015) Any therapy that could prolong patient’s life or improve the quality of her 
life in the last stages of the disease would be a welcomed by the sufferers and 
their families. Unfortunately, to date, the therapies available failed to deliver 
significant improvements. This issue has many facets, but the main one would be 
that PDAC is driven by several genes as described in section 6.4 Genetic 
Background of Pancreatic Ductal Adenocarcinoma, while the therapies available 
target specific pathways. Since these pathways relate to specific genes, if the 
expressed genes do not activate certain pathway, the therapeutic agent will not 
deliver the anticipated benefits while exposing patients to many adverse effects 
from chemotherapy.  
Many in vitro and pre-clinical in vivo trials show that therapeutic efficacy of 
drugs depends on the genes driving the disease. The latter relies on animal 
models, which KPC and KC Pten mouse models are example of. Both models 
recapitulate well human PDAC, and although they show similar clinical signs and 
survival, they are being driven by different pathways. Finding therapeutic 
approaches that work in those mouse models is the key to help a subset of 
patients, whose tumours are driven by the same genes.  
Even though it has been established that TGFβ plays an important role in 
tumourgenesis, the exact circumstances upon which it switches its function from 
tumour-supressing to tumour-driving are not well understood. However, since its 
pathway is active throughout the cancer development, TGFβ presents itself as an 
attractive therapeutic target that could potentially arrest the switch from 
benign tumours to aggressive carcinoma in situ and further – the metastatic 
spread. 
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7 Aims and objectives 
7.1 mTOR Inhibitor study 
The mTOR pathway has been previously shown to be driving PDAC in the sub-set 
of tumours lacking tumour supressing Pten gene. (Kennedy et al., 2011; Thorpe 
et al., 2015) The aim of the study was to compare the efficacy of mTOR inhibitor 
Rapamycin in KC Pten and KPC mouse models of PDAC. This was done by 
conducting in vitro and in vivo experiments, which were all a collaborative 
effort. Shown and discussed here are the results of the in vivo study using 18F-
FLT PET/CT, which compares proliferation in those mouse models before and 
after treatment. 
7.2 TGFβ Study 
The aim of the TGFβ antibodies study was to assess if combining anti-TGFβ 
antibody with Gemcitabine would be more effective than Gemcitabine 
monotherapy in the treatment of PDAC. This was done by observing its acute 
(24±2h post-injection) effect on proliferation using 18F-FLT and ex vivo 
techniques like gamma counting, autoradiography and Ki68 
immunohistochemistry. 
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8 Methods 
8.1 mTOR Inhibitor Study 
8.1.1 Study Design 
 Two cohorts of mice (n=3) were compared. All animals were genetically 
engineered using Cre-Lox system to conditionally express or delete genes within 
Pdx-1 (pancreatic and duodenal homeobox1 promoter) expressing tissues. The 
first group expressed mutated Kras in one allele and lacked Pten on both alleles: 
KrasG12D/+; Pten-/-; Pdx1-Cre and will be henceforth called KC Pten. The control 
cohort expressed mutated Kras and Tp53 genes on one of the alleles and wild-
type copies of those genes on the other one: KrasG12D/+; Tp53R172H/+; Pdx1-Cre 
(henceforth called KPC). 
8.1.2 Treatment Regime and Sampling 
Upon detecting palpable tumour and confirming the finding by ultrasound 
(Vevo770 System with 35 MHz Real-Time Micro Visualisation VisualSonics 
scanhead), mice were imaged using PET/CT (Bruker Albira tri-modal 
PET/SPECT/CT system with 2-ring PET) and 18F-FLT to establish base-line 
proliferation profile. Subsequent treatment commenced with mice receiving 
intraperitoneal injections: daily of rapamacin (10 mg/kg) or vehicle, and/or of 
gemcitabine (100 mg/kg) twice weekly. After four days of treatment the second 
PET/CT imaging study was conducted. Mice were then sacrificed and necropsy 
conducted. Tumours were excised, fixed in 10% buffered formalin solution, 
paraffin-embedded and then sectioned. H&E and Ki67 staining was performed on 
the section near the middle of the tumour. 
8.1.3 PET/CT Protocol 
To establish a baseline and the best time-point for imaging, the first mouse was 
anaesthetised using a mixture of 5% isoflurane and medical air, and 
intravenously (i.v.) injected with 3.33 MBq of 18F-FLT via tail vein. It was then 
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placed on the imaging bed and imaged for a continuous period of 3h using 
dynamic PET protocol containing a series of 1 min frames and followed a CT scan 
(600 projections, 45 kV, 0.2 mA).  
Subsequent mice were, under anaesthesia, injected with 6-8 MBq each of 18F-FLT 
to compensate for the decay over the 2h (conscious) uptake period. They were 
then imaged using a static, 1h PET scanning protocol (40 mm bed offset) 
followed by the 2-bed-position CT (600 projections, 35 kV, 0.4 mA, 25 mm bed 
offset). The subsequent scans were changed to single bed CT protocol and the 
offset was adjusted to 40 mm, so the abdomen was clearly visible within the 
FOV. 
8.1.4 Data Analysis 
PET/CT images were reconstructed using the Albira Reconstructor software using 
the default reconstruction parameters: MLEM 12 iterations, 80×80×94 FOV, 
1×1×0.944 mm voxel size for PET images, and FBP 0.25×0.25×0.25 mm voxel size 
for CT ones.  Reconstructed images were analysed using PMOD software and 
after the co-registration feature was used to ensure good alignment between the 
pictures. CT images did not have enough soft tissue contrast to delineate organs 
within the abdominal cavity. However, they were used as a reference on which 
lungs could be easily identified and from there liver could be found. Since the 
tracer is excreted with urine, it accumulates in the bladder, which was hence 
outlined: first a 3D ball slightly bigger than the bladder was drawn (preview tool 
allowing for tracking the VOI appearance in all directions was used to align it) 
and next threshold it to 10% of the hottest pixel within the FOV to focus it only 
over the bladder. The inspector tool was used to inspect the uptake values 
around the bladder, so when the VOI contains only bladder a masking tool can be 
used to mask this volume using an average uptake value from the tissues around.   
In the next stage, hot spots were searched for within the abdomen and VOIs 
were manually drawn on each image slice to contain those hot spots.  
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8.2 Gamma counter experiments 
8.2.1 Calibration 
Starting with 3.0, 3.0 and 3.05 MBq three dilution series (log2) were prepared. 
The volume of the individual sample was 0.6 ml and was placed in 1.5 ml screw-
top vials. Before the start of the experiment 2-3 empty cassettes were measured 
to acquire background counts and ensure there was no residual contamination on 
the cassettes. All samples were then loaded onto gamma counter (Packard Cobra 
II, Perkin-Elmer, Waltham, MA, US) and counting started using pre-set protocol 
no 7, set up for 18F and which has three energy windows defined: 
 15 to 2000 keV, 
 311 to 711 keV,  
 722 to 1222 keV, 
Counting time was 1 min.  
Decay-corrected activity was calculated for each vial using 18F half-life and an 
actual time each sample was measured.  
8.2.2 Sample volume experiment 
Background counts were acquired as above. A known activity (50 kBq at a 
reference time) was prepared in 1.5 ml screw-top vials in a range of volumes, 
from 100 ml to 1500 ml, every 100 ml in triplicate. The samples were then 
measured three times using gamma counter (1 min counting time). Counts from 
the energy window of 311 to 711 keV and 15 to 2000 keV were decay-corrected 
to the reference time. For each volume, the counts were averaged and standard 
error of the mean calculated. A line was fitted to these data points to show if 
there is a linear relationship between the counts measured depending on the 
volume of the sample. 
A ratio of the counts measured in the 15 to 2000 keV and 311 to 711 keV was 
also calculated using non-decay-corrected data. 
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8.3 TGFβ Antibody 
8.3.1 Study Design 
The effects of an anti-TGFβ antibody were observed in a cohort of KPC mice, 
which were divided into two groups: mice, which received a single i.p. injection 
of Gemcitabine and mice, which received a single dose of Gemcitabine like the 
first group and at the same time were injected also with anti-TGFβ antibody. 
24±2 hours following the first injection the mouse was injected with a dose of 
18F-FLT i.v. After 2 more hours animals were sacrificed and following tissues 
harvested for gamma counting. Tissues marked with asterisk (*) from the list 
below were also assessed using autoradiography: 
 blood, 
 heart, 
 lungs, 
 spleen, 
 kidney, 
 stomach, 
 small intestine, 
 large intestine, 
 tumour *, 
 liver *, 
 muscle, 
 brain. 
Gamma counting, autoradiography and Ki67 staining were performed on all or a 
sub-set of the samples. For technical reasons (problems during 18F-FLT 
production, broken cryostat or film processor) it was not always possible to 
complete all three tests on all the mice in the study – details were gathered in 
Table 10. 
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Table 10 Summary of the number of mice used in the study and tests 
conducted on harvested samples 
Protocol 
Gamma 
counting 
Autoradio- 
graphy 
IHC 
All three 
completed 
Ctrl WT 9 6 10 6 
Gem 8 7 10 7 
Gem + α-TGFβ 8 7 10 7 
Gem + ab10517 5 5 5 5 
Gem + ab64715 3 2 5 2 
8.3.2 Treatment Regime 
Mice in the treatment group were given a single injection of Gemcitabine (100 
mg/kg) intraperitoneally (i.p.) or the same dose of Gemcitabine with the 
additional injection of 100 μg of anti-TGFβ antibody (ab10517 or ab10517, 
Abcam, Cambridge, UK) via the same route. This treatment was administered 
24±2h before the scheduled experiment. Table 11 shows the details of the age of 
mice used in the experiment in each of the sub-groups, their average weights 
and average dose of 18F-FLT, which mice received prior to being sacrificed. 
Table 11 Summary of an average mice age, weight and the dose of 18F-FLT 
administered 
Protocol Avg Age [days] 
Avg Activity 
[MBq] 
Avg weight [g] 
Ctrl WT 125.1 9.3 25.9 
Gem 114.5 9.0 26.4 
Gem + α-TGFβ 124.8 9.4 26.8 
Gem + ab10517 146.8 9.5 27.5 
Gem + ab64715 102.8 9.3 25.5 
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8.3.3 Gamma Counting 
Gamma counting was performed using Packard Cobra II (Perkin-Elmer, Waltham, 
MA, US; Figure 30) and pre-set protocol, which defines three energy windows to 
distinguish between all, true and scattered events: 
 15 to 2000 keV, 
 311 to 711 keV,  
 722 to 1222 keV. 
Measurement time for each sample was 60 s and the latency between samples 
was 40 s. Before the start of the experiment 2-3 empty cassettes were measured 
to acquire background counts and ensure no residual contamination on the 
cassettes is present. All samples were placed during dissection in the screw-top 
1.5 ml tubes and loaded onto cassettes. After choosing an appropriate command 
on the computer screen, the samples were measured automatically. Before 
experiment tubes containing PDAC tumour, liver, small and large intestine, were 
additionally filled with 0.5 ml of 10% buffered formalin since those samples were 
later passed for histological processing. All tubes were pre-weighed before the 
experiment and again after the gamma counting (after an overnight storage 
which allowed for the radioactivity to decay away to background levels). 
Subtraction of the pre- and post-weights allowed for the determination of the 
organ weight.  
For each mouse between the time of the injection with 18F-FLT and animal 
sacrifice three controls were prepared in 0.5 ml of PBS: 
 negative control, 
 1/100 of the injected dose, 
 1/200 of the injected dose. 
The negative control provided a volume-adjusted background measurement 
value, which was used to calculate actual counts for each tissue. The activities 
within each excised organ expressed in kBq or percentage of the injected dose 
could be found using the latter two controls. 
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Correcting for the decay of 18F, normalizing for mouse weight and injected dose 
(described below), counts per gram of tissue could be calculated for all sampled 
organs. All results were automatically printed by the attached dot matrix printer 
and written down from the computer screen into an Excel worksheet (as shown 
in the Appendix). 
 
 
Figure 30 Cobra II Gamma Counter with samples loaded onto cassettes and 
photon counting process in progress. On the right perforated paper hangs 
from the dot-matrix printer, which prints the results in real-time. The last  
10 results are also displayed on the computer screen. 
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8.3.4 Autoradiography 
Parts of the pancreatic and liver tissue were frozen at the time of the dissection 
using cryo-spray and transported on dry ice out of the animal facility into the 
Histology laboratory. An empty and clean sample disk was placed inside the 
microtome cryostat chamber, which was set to -20℃. After a few minutes during 
which it cooled down, a small amount of OCT (optimal cutting temperature) 
compound was poured onto it to cover the area slightly bigger than a sample 
that was to be cut. When OCT started to solidify (indicated by the change of 
colour from transparent to white) the sample was placed on top of the disk, so it 
became partially embedded in OCT and stuck to it. Then more OCT was poured 
around the sample to create, after solidification, a frozen block with the sample 
embedded in it. Care was taken to fill any cavities and avoid air bubbles that 
could disrupt the smoothness of the cutting process and, in effect, damage the 
cut section.  
When the OCT with the embedded sample froze, the sample disk was mounted in 
the cryostat microtome rig (Leica CM1950, Leica Microsystems, Milton Keynes, 
UK). A few 100 μm sections were cut using the coarse setting to expose the 
deeper layers of the tissue. Then sections of the same thickness were cut using 
the fine setting and gently transferred onto positively charged slides (Surgipath 
Snowcoat range, Leica Microsystems, Milton Keynes, UK) with care taken to 
avoid sample rolling, breaking, folding or creases. Each slide was placed in the 
plastic slide storage box ensuring sufficient space between the slides. When all 
slides containing cut sections from a given mouse were cut, the box was taken to 
a dark room and transferred to a light-tight cassette. A photographic film was 
subsequently applied (Kodak Biomax MR, Carestream Health, Rochester, NY, US) 
under dim red light and the cassette closed. Each cassette was then additionally 
put in a black, light-tight sleeve and placed in a -20℃ freezer in a controlled-
access radiation room.  
After overnight storage, which allowed for a decay of 18F to a background level, 
each cassette was opened in the dark room and film was developed using an 
automatic X-ray film processor. Developed autoradiography films from each 
experiment were later scanned using BioRad GS-800 Calibrated Densitometer 
(BioRad Laboratories, Hemel Hempstead, UK) and Quantity One 1-D Analysis 
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Software (the same vendor as the densitometer) and, using the same software, 
every scan was then exported as TIFF image and saved onto portable media 
drive. 
Each TIFF image was opened in ImageJ software, version 1.4 (National Institutes 
of Health, Bathesda, Maryland, US). (Rasband, 1997-2016) Five rectangular 
regions of interest (ROI) were drawn using the Rectangular Selection tool. Next, 
ten ROIs were drawn for each tissue (liver or PDAC) using the Freehand Selection 
tool (Figure 31). All ROIs were added to the ROI Manager plugin in which Set 
Measurement option was selected and the following options chosen: Area, Mean 
(within the area), StdDev, Max and Min. After clicking “Measure” in the ROI 
Manager the measurements were taken and then saved to an Excel spreadsheet. 
The representative values for the investigated tissues were calculated by 
averaging measurements of all ten ROIs and by subtracting the average of the 
background ROIs. Results for all mice were then summarised in a separate 
spreadsheet, where normalization (described below) was performed. 
127 
 
 
Figure 31 An example scan of an autoradiography film presenting images of 
100 μm sections of liver and pancreas along with the regions of interest 
chosen in the analysis process in ImageJ software 
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8.3.5 Ki67 
Formalin-fixed paraffin-embedded tissue (tumour or liver) was cut into 4 μm 
sections. Sections were then deparaffinised and stained using an automated 
protocol on Autostainer Link 48 (Dako, Ely, UK). The antibodies and reagents 
used were as follows:  
 primary antibody – anti-Ki67 (SP6 RM-9106, Thermo Fisher Scientific, 
Waltham, MA, US), dilution 1/100, 
 amplification step – Rabbit Envision kit (Dako, Ely, UK), 
 visualisation substrate – liquid DAB (3,3’ diaminobenzidine) peroxidase 
substrate (Dako, Ely, UK) 
 counterstain – Gill’s Haematoxylin (RHS-335, CellPath, Newtown, UK). 
From each sample one section from the middle was cut and stained. It was then 
scanned in full at 20x magnification using a slide scanner (SCN400F, Leica 
Biosystems, Milton Keynes, UK) and uploaded onto a digital image server 
operating within the local network.   
New Tissue Image Analyser protocols were defined. Their details for tumour and 
liver tissues are given in Table 12. Each slide was manually evaluated and ROIs 
containing tissues either to include (actual liver, pancreatic or tumour) in or 
exclude (fat, lymph nodes, small intestine, etc.) from the analysis were 
selected. Once this was done for few slides, they were selected for batch 
processing, defined protocol was selected and the job submitted to the server. If 
the sample contained healthy and cancerous areas, both were used in analysis. 
Only the areas not containing liver or pancreatic/tumour tissues were excluded.  
After the job was processed, an output CSV file could be generated. The value 
used in the comparative analysis among animals subjected to the investigated 
treatments was a percentage of the positively-stained nuclei, which reflects the 
Ki67-expressing (i.e. proliferating) nuclei.  
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Table 12 Details of the Leica Tissue IA automatic scoring protocol defined and used for the assessment of PDAC and liver 
tissues stained with anti-Ki67 antibody 
 PDAC Liver 
Data Input Parameter Value 
0=µm, 1=mm, 2=pixels 0 0 
Segment Tissue from Background by Intensity 170 170 
0=Nuclei are similar, >=1, Nuclei increasingly diverse (darkest to lightest) 2 3 
0=Strong Nuclear Counterstaining, 2=Weak Nuclear Counterstaining 2 2 
Values in units 37 37 
Eliminate nuclei with area outside this range (specified in units squared) 0 0 
Eliminate nuclei with density outside this range 0 0 
Eliminate nuclei with nuclear area density outside this range (specified in units squared) 0 0 
Eliminate cells with area outside this range (specified in units squared) 0 0 
Values in units 100 100 
Above this value pixels are identified as negative 200 200 
Eliminate nuclei with a % below this value 10 10 
Identify nuclei having strong/moderate/weak staining intensity 99 99 
Above this value pixels are identified as negative 220 220 
Eliminate areas with a % below this value 75 75 
Identify areas having strong/moderate/weak staining intensity 160 160 
Above this value pixels are identified as negative 220 220 
Eliminate areas with a % below this value 75 75 
Identify areas having strong/median/weak staining intensity 160 160 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = Include only Negative Cells 0 0 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = Include only Negative Cells 0 0 
0 = Include All Cells, 1 = Include only Positive Cells, 2 = Include only Negative Cells 0 0 
Default Calibration 1 1 
   
File Input Parameter Name 
Colour Definition File deconvolution-Haematoxylin 
Colour Definition File deconvolution-DAB  
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8.3.6 Normalization 
Before effects of the selected treatment could be compared it was necessary to 
normalize the results of gamma counting and autoradiography measurements to 
consider the weight of the mouse and dose of the radiotracer administered. The 
approach adopted was like the calculation of the standard uptake value (SUV) 
used in the analysis of PET images, in particular in the clinical practice, where 
the weights of patients may vary significantly. On the PET image the value 
measured is the concentration of the trapped and free tracer (and its radio-
labelled metabolites) in each volume of interest (VOI), e.g. an organ or part of 
it. For example, in the Albira the reconstructed PET images in microPET format 
are calibrated to display kBq per cc.  
SUV is defined as follows: 
QR = 	S5 T,  
where subscript t denotes value at a given time, A - activity concentration 
measured on an image, ID – injected dose and w – weight. 
The normalized value, expressed as SUV is therefore a measured value (in this 
case, an activity concentration) multiplied by a factor calculated as a ratio of 
patient or subject weight to injected dose. 
In a similar fashion one can calculate normalized values of gamma counts per 
gram of tissue or optical density measured over certain region of interest (area) 
on autoradiography images of all investigated tissues. Ki67 staining does not 
depend on the weight of the mouse, neither does it depend on the dose of 18F-
FLT and therefore does not require normalization. 
8.3.7 Statistical Data Analysis 
Statistical analysis of the data was performed by Dr. Gabriela Kalna from the 
Computational Biology and Bioinformatics team in the CR UK Beatson Institute. 
The normalized counts per gram calculated as explained above were log2-
transformed and analysed considering two factors - type of tissue and treatment 
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protocol. The empirical Bayes adjusted p-values and fold changes were 
calculated using R package limma. (Ritchie et al., 2015; Smyth, 2004) 
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9 Results 
9.1 mTOR Inhibitor Study 
Figure 32 highlights the challenges posed by the low soft-tissue contrast 
encountered in CT imaging. Some organs could be approximately delineated 
based on the anatomical reference posed by the skeletal structure. Some (e.g. 
duodenum or bladder) are visible slightly better due to the natural contrast 
provided by the water. It is not possible, however, to tell with certainty where 
do the edges of the liver lie, where are kidneys, spleen, and stomach. More 
importantly for this experiment, it is also not possible to distinguish the PDAC 
tumour from the surrounding small and large intestine. One can see that the 
abdominal cavity does not have uniformly grey appearance. Yet it may be 
difficult to interpret the findings based on CT alone. For example, one can see 
that there are places in the abdomen that appear black. This may be simply gas 
trapped in the gastro-intestinal tract, but can indicate as well, a tumour that 
has a cyst. 
Figure 33 presents the fused PET/CT image of a KC Pten mouse (same as above) 
injected with 18F-FLT and imaged using dynamic PET over 3 hours followed by 
the CT. The image was created by averaging all the 1-min acquisitions over the 
last hour of the PET scan to reduce noise. Most of the tracer and its metabolised 
accumulated in the bladder, therefore a VOI around the bladder was drawn and 
masked to the average level of activity immediately outside it. This removed 
very high activity concentrations from the image and allowed for better visual 
contrast on the image, which immediately revealed PDAC tumour. The outline of 
the liver is also visible on the sagittal slice of the image. 
Figure 34 shows the time activity curves for liver and PDAC. Beyond 60 min liver 
uptake stabilizes, while in the tumour raises all the way until the end of the 
scan. At 60 min, in fact, the uptake in both organs appeared to be the same, 
which would make it very difficult to distinguish them if the scan was stopped 
then. After the second hour of the scan the difference in the uptakes should be 
clearly visible, which the previous image (Figure 33) is an example of. 
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Figure 32 CT image of the mouse injected with 18F-FLT. Soft-tissue contrast 
does not allow for the accurate distinction among particular organs. 
However, based on the skeletal structure, which is clearly visible, one can 
approximate their position. 
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duodenum 
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Figure 33 Fused PET/CT image on which bladder was masked with uniform, 
low-density volume. This led to the enhancement of the PET image contrast 
and made the tumour a prominent feature that would otherwise be difficult 
to distinguish from the surrounding high-proliferative intestine. 
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kidney 
kidney 
masked bladder 
masked bladder 
liver 
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Figure 34 Time-activity curves presenting average activity (kBq/cm3) for liver 
and tumour measured over a period of over 3h using 1 min frames. 
 
Figure 35 to Figure 37 present the effects of mTOR inhibitor treatment on KC 
Pten mouse using different modalities, 18F-FLT PET/CT, H&E and Ki67 IHC. 
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Figure 35 PET/CT image of KC Pten mouse treated with rapamacin and 
injected intravenously with 18F-FLT. Long arrow points to PDAC tumour, 
while the other marker shows the acumulation of the tracer in the bladder. 
Picture taken from (Morran et al., 2014). 
 
 
Figure 36 H&E staining presenting the effects of rapamycin treatment on 
PDAC tumours spontaneously developed by mice of two distinct genetic 
backgrounds. Picture taken from (Morran et al., 2014). 
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Figure 37 Ki67 staining on pancreatic adenocarcinoma tissues presenting the 
effects of rapamacin treatment on tumour proliferation in KC Pten and KPC 
mice. Picture taken from (Morran et al., 2014). 
 
 
Figure 38 Tumour uptake of 18F-FLT measured on PET image as maximum 
pixel value and normalised to liver. The graph shows individual results for 
two cohorts of three mice (KC Pten and KPC) before and after rapamacin 
treatment. Graph taken from (Morran et al., 2014). 
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9.2 Gamma counter Calibration 
9.2.1 Calibration 
Figure 39 presents counts measured within one minute from three dilution (log2) 
series. Each measurement consists of counts registered in one of three (partially 
overlapping) energy windows. The activity of each sample is presented as decay-
corrected to account for the time elapsed between the time when samples were 
prepared and the time of measurement. Samples higher in the dilution series 
and of activity above ca. 300 kBq (at the time of measurement) are not shown 
on the plot as they fall outside the resolution of the gamma counter, i.e. lead to 
the detector saturation and subsequent computer freeze. Within the measured 
range, however, i.e. 275 kBq to 80 Bq the counts showed good linearity within 
all three energy windows.  
 
Figure 39 Calibration curve showing linear relationship within the measured 
range of activities within three energy windows. 
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9.2.2 Sample volume 
Figure 40 shows how the ratio between the counts measured in the energy 
window of 15 to 2000 keV and 311 to 711 keV changes. The relationship is 
exponential with R2 = 0.98. Figure 41 summarizes how the sample volume 
impacts the measured number of photons. Individual points are the average of 
triplicate samples prepared within the given volume and the error bars reflect 
the standard error of the mean within those three samples. All data points were 
decay-corrected and the almost horizontal line is a linear fit of all points shown. 
 
 
Figure 40 The ratio of counts in the energy window of 15 to 2000 keV to 
those in 311 to 711 keV depending on the volume of the sample. 
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Figure 41 Relationship between the sample volume and measured counts. 
The linear fit is nearly horizontal, which means that within the range 
measured (100-1500 μl) the sample volume has very little effect on gamma 
photons measured by the counter. 
 
 
9.3 TGFβ Antibody Study 
9.3.1 Gross Anatomy 
Figure 42 to Figure 47 present examples of gross anatomy findings at necropsy, 
which reflect the heterogeneity of PDAC in mice, but also in men. Shown 
conditions may have impact on variable results of the experiment.  
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Figure 42 Large pancreatic cyst filled with fluid surrounded by fibrous 
tumour stroma.  
 
 
Figure 43 Blocked bile duct leading to its subsequent dilation and jaundice.  
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Figure 44 Tumour encapsulating enlarged spleen. 
 
 
Figure 45 Blocked bile duct and macroscopic liver metastases. 
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Figure 46 Tumour cells blocking part of the duodenum causing retention of 
bile within it. 
Tables 13 to 24 correspond to individual organs measured using the gamma 
counter. The tables present the results of the Bayesian t-test performed on the 
samples. Mice are grouped into cohorts and those cohorts are compared with 
each other. Subsequent columns show log2 of fold change between the average 
result for the compared cohorts and p-value as the measure of statistical 
significance. Since the p-value between the cohorts treated with different 
antibodies is for all organs greater than 0.5 it can be assumed that there is no 
statistically significant difference between the effects of those antibodies 
measured by the gamma counting and therefore those antibodies can be pooled 
together. In the last two rows of each table the comparison is made between the 
cohort made up of all mice treated with the antibody and either untreated, or 
gemcitabine-only treated groups.  
Figure 47 summarizes the biodistribution of 18F-FLT and its metabolites measured 
using the gamma counter. Four groups of mice are distinguished, i.e. untreated, 
gemcitabine monotherapy and gemcitabine with one of two antibodies-treated. 
This figure confirms the results of the analyses provided in the above tables, 
specifically that there is not enough evidence to support the existence of a 
statistically significant difference (or lack of it) between the pairs of compared 
cohorts for any of the sampled organs.  
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Figure 47 Biodistribution of 18F-FLT and its metabolites 2hrs after injection as measured by the gamma counter.
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Table 13 Liver 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.07013 0.9196 
Gemcitabine + ab64715 Untreated control -0.1987 0.8349 
Gemcitabine + ab10517 Untreated control -0.0432 0.9568 
Gemcitabine + ab64715 Gemcitabine -0.2688 0.7813 
Gemcitabine + ab10517 Gemcitabine -0.1134 0.8894 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.1554 0.8816 
Gemcitabine + antibody Untreated control -0.1787 0.9403 
Gemcitabine + antibody Gemcitabine -2.6464 0.2854 
 
Table 14 PDAC 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.5103 0.5047 
Gemcitabine + ab64715 Untreated control 0.5513 0.5989 
Gemcitabine + ab10517 Untreated control -0.5059 0.5642 
Gemcitabine + ab64715 Gemcitabine 0.0410 0.9692 
Gemcitabine + ab10517 Gemcitabine -1.0161 0.2606 
Gemcitabine + ab10517 Gemcitabine + ab64715 -1.0571 0.3593 
Gemcitabine + antibody Untreated control -0.1094 0.8856 
Gemcitabine + antibody Gemcitabine -0.6197 0.4307 
 
Table 15 Blood 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.1647 0.8114 
Gemcitabine + ab64715 Untreated control -0.3105 0.7432 
Gemcitabine + ab10517 Untreated control 0.0690 0.9307 
Gemcitabine + ab64715 Gemcitabine -0.4752 0.6218 
Gemcitabine + ab10517 Gemcitabine -0.0958 0.9059 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.3795 0.7148 
Gemcitabine + antibody Untreated control -0.0733 0.9143 
Gemcitabine + antibody Gemcitabine -0.2381 0.7343 
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Table 16 Brain 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.2188 0.6827 
Gemcitabine + ab64715 Untreated control -0.3794 0.6056 
Gemcitabine + ab10517 Untreated control -0.0269 0.9650 
Gemcitabine + ab64715 Gemcitabine -0.5982 0.4240 
Gemcitabine + ab10517 Gemcitabine -0.2457 0.6955 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.3525 0.6613 
Gemcitabine + antibody Untreated control -0.1591 0.7633 
Gemcitabine + antibody Gemcitabine -0.3779 0.4882 
 
Table 17 Heart 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.0918 0.8992 
Gemcitabine + ab64715 Untreated control -0.4493 0.6518 
Gemcitabine + ab10517 Untreated control 0.1072 0.8975 
Gemcitabine + ab64715 Gemcitabine -0.5412 0.5928 
Gemcitabine + ab10517 Gemcitabine 0.0154 0.9856 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.5565 0.6101 
Gemcitabine + antibody Untreated control -0.1015 0.8874 
Gemcitabine + antibody Gemcitabine -0.1933 0.7933 
 
Table 18 Kidney 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.2142 0.7311 
Gemcitabine + ab64715 Untreated control -0.3547 0.6783 
Gemcitabine + ab10517 Untreated control -0.3833 0.5925 
Gemcitabine + ab64715 Gemcitabine -0.5689 0.5133 
Gemcitabine + ab10517 Gemcitabine -0.5975 0.4157 
Gemcitabine + ab10517 Gemcitabine + ab64715 -0.0286 0.9756 
Gemcitabine + antibody Untreated control -0.3726 0.5445 
Gemcitabine + antibody Gemcitabine -0.5868 0.3555 
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Table 19 Large intestine 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.5125 0.4267 
Gemcitabine + ab64715 Untreated control 0.2507 0.7553 
Gemcitabine + ab10517 Untreated control 0.0227 0.9733 
Gemcitabine + ab64715 Gemcitabine -0.2619 0.7553 
Gemcitabine + ab10517 Gemcitabine -0.4898 0.4974 
Gemcitabine + ab10517 Gemcitabine + ab64715 -0.2280 0.7927 
Gemcitabine + antibody Untreated control 0.1082 0.8531 
Gemcitabine + antibody Gemcitabine -0.4043 0.5229 
 
Table 20 Lungs 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.1357 0.8477 
Gemcitabine + ab64715 Untreated control -0.4439 0.6475 
Gemcitabine + ab10517 Untreated control 0.2392 0.7682 
Gemcitabine + ab64715 Gemcitabine -0.5796 0.5569 
Gemcitabine + ab10517 Gemcitabine 0.1034 0.9007 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.6830 0.5213 
Gemcitabine + antibody Untreated control -0.0170 0.9807 
Gemcitabine + antibody Gemcitabine -0.1527 0.8322 
 
Table 21 Muscle 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control -0.4059 0.61580 
Gemcitabine + ab64715 Untreated control -1.0352 0.3532 
Gemcitabine + ab10517 Untreated control -0.5507 0.5534 
Gemcitabine + ab64715 Gemcitabine -0.6293 0.5767 
Gemcitabine + ab10517 Gemcitabine -0.1448 0.8785 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.48451 0.6900 
Gemcitabine + antibody Untreated control -0.7324 0.3612 
Gemcitabine + antibody Gemcitabine -0.3265 0.6909 
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Table 22 Small intestine 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.5673 0.4415 
Gemcitabine + ab64715 Untreated control -0.1408 0.8889 
Gemcitabine + ab10517 Untreated control 1.0703 0.2093 
Gemcitabine + ab64715 Gemcitabine -0.7081 0.4901 
Gemcitabine + ab10517 Gemcitabine 0.5030 0.5601 
Gemcitabine + ab10517 Gemcitabine + ab64715 1.2110 0.2765 
Gemcitabine + antibody Untreated control 0.6161 0.4049 
Gemcitabine + antibody Gemcitabine 0.0488 0.9486 
 
Table 23 Spleen 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control -0.4676 0.4179 
Gemcitabine + ab64715 Untreated control -1.2169 0.1293 
Gemcitabine + ab10517 Untreated control -0.7370 0.2682 
Gemcitabine + ab64715 Gemcitabine -0.7493 0.3523 
Gemcitabine + ab10517 Gemcitabine -0.2694 0.6897 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.4799 0.5791 
Gemcitabine + antibody Untreated control -0.9169 0.1134 
Gemcitabine + antibody Gemcitabine -0.4493 0.4444 
 
Table 24 Stomach 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control -0.2992 0.6365 
Gemcitabine + ab64715 Untreated control -0.9611 0.2721 
Gemcitabine + ab10517 Untreated control -0.4512 0.5352 
Gemcitabine + ab64715 Gemcitabine -0.6619 0.4541 
Gemcitabine + ab10517 Gemcitabine -0.1520 0.8376 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.5099 0.5921 
Gemcitabine + antibody Untreated control -0.6424 0.3079 
Gemcitabine + antibody Gemcitabine -0.3432 0.5946 
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9.3.2 Autoradiography 
Tables 25 and 26 gather results of a Bayesian t-test for liver and PDAC measured 
using autoradiography. Again, there is not enough evidence to confirm or disprove 
the existence of the statistically significant difference among the organs in 
question between any of the pairs of cohorts.  
 
Table 25 Liver 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 1.1183 0.1920 
Gemcitabine + ab64715 Untreated control 0.9301 0.4251 
Gemcitabine + ab10517 Untreated control 0.7655 0.3860 
Gemcitabine + ab64715 Gemcitabine -0.1882 0.8675 
Gemcitabine + ab10517 Gemcitabine -0.3528 0.6740 
Gemcitabine + ab10517 Gemcitabine + ab64715 -0.1645 0.8868 
Gemcitabine + antibody Untreated control 0.8125 0.3087 
Gemcitabine + antibody Gemcitabine -0.3058 0.6833 
 
Table 26 PDAC 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control 0.7433 0.3291 
Gemcitabine + ab64715 Untreated control 0.1595 0.8779 
Gemcitabine + ab10517 Untreated control 0.2529 0.7476 
Gemcitabine + ab64715 Gemcitabine -0.5838 0.5663 
Gemcitabine + ab10517 Gemcitabine -0.4904 0.5165 
Gemcitabine + ab10517 Gemcitabine + ab64715 0.0934 0.9283 
Gemcitabine + antibody Untreated control 0.2262 0.7493 
Gemcitabine + antibody Gemcitabine -0.5171 0.4449 
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9.3.3 Ki67 
Figure 48 to Figure 52 show example results of the anti-Ki67 IHC. Because the 
results showed no clear difference in the Ki67 expression among the treated and 
untreated specimen, those images are given as an example of typical Ki67 pattern 
observed in PDAC in KPC model, including liver metastasis and intestines.  
 
 
Figure 48 Liver metastasis in a mouse treated with anti-TGFβ antibody (x4 & 
x20 magnifications)  
 
 
100μm 
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Figure 49 Example expression of Ki67 in large intestine (x10 magnification)  
 
 
Figure 50 Example expression of Ki67 in the small intestine (x10 magnification) 
100μm 
100μm 
100μm 
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Figure 51 Ki67 expression in the PDAC tumour showing still some normal acinar 
cells and with highlighted region (dotted line) of desmoplasia (x20 
magnification). 
 
  
Figure 52 Ki67 expression of Ki67 in the untreated advanced PDAC tumour (x10 
magnification) 
100μm 
100μm 
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Figure 53 presents a screen-shot of the metadata file containing the results of the 
analysis of the sample using automated Leica Tissue IA tool.  
 
Figure 53 Example output data of the automatic Tissue IA tool. 
 
In Tables 27 and 28 are shown the results of the Bayesian t-test of the percentage 
of the positively-stained (proliferating) nuclei within the sample. As marked, only 
two cohorts show some statistical difference in the liver: gemcitabine 
monotherapy group and the gemcitabine with the TGFβ-antibody ab10517 show 
lower proliferation when compared with the untreated control. No analogous (or 
154 
 
otherwise) evidence emerges from the analysis of the PDAC/pancreas samples that 
would support or fail to support that significant difference exists among any of the 
treatment groups. 
Table 27 Liver 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control -0.5579 0.0623 
Gemcitabine + ab64715 Untreated control -0.4765 0.1530 
Gemcitabine + ab10517 Untreated control -0.9920 0.0260 
Gemcitabine + ab64715 Gemcitabine 0.0814 0.9871 
Gemcitabine + ab10517 Gemcitabine -0.4341 0.4214 
Gemcitabine + ab10517 Gemcitabine + ab64715 -0.5155 0.5261 
Gemcitabine + antibody Untreated control -0.7629 0.9403 
Gemcitabine + antibody Gemcitabine -0.2050 0.2854 
 
Table 28 PDAC 
Cohort 1 Cohort 2 log2FC p value 
Gemcitabine Untreated control -0.3188 0.3165 
Gemcitabine + ab64715 Untreated control -0.4258 0.7659 
Gemcitabine + ab10517 Untreated control -0.6071 0.9006 
Gemcitabine + ab64715 Gemcitabine -0.1071 0.6500 
Gemcitabine + ab10517 Gemcitabine -0.2884 0.3481 
Gemcitabine + ab10517 Gemcitabine + ab64715 -0.1813 0.7156 
Gemcitabine + antibody Untreated control -0.5266 0.9289 
Gemcitabine + antibody Gemcitabine -0.2078 0.3679 
 
Figure 54 gathers the results of all three methods of measuring proliferation in the 
livers or pancreata of the mice belonging to any of the sub-groups specified above.  
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Figure 54 Summary of the acute effects of anti-TGFβ on KPC mice. Each row of 
graphs presents results obtained using a different technique, which can be 
used to complement and validate PET imaging. Control denotes untreated mice. 
Refer to Table 10 for the sample size in each of the groups.
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10 Discussion 
10.1 mTOR 
The investigation of mTOR inhibition in two distinct cancer models used both in 
vitro and in vivo approaches to characterize effects of rapamacin on PDAC. In 
vitro studies were conducted by Douglas Morran and aimed at understanding the 
mechanisms of action of rapamacin on pancreatic cancer tumour cells, which are 
not fully understood. Discussed below is the in vivo part of the study, which 
involved PET/CT imaging and data analysis. 
The results of the PET/CT imaging complement well the in vitro results in that 
rapamacin showed beneficial effects on mice of KC Pten phenotype, but none on 
the KPC ones. This is in concordance with the in vitro results and the 
experimental hypothesis. The use of 18F-FLT allowed for visualisation of 
proliferation in the tumour, which was expected to be negatively affected by 
rapmacin. Indeed, that appeared to be the case for KC Pten mice that were 
imaged.  
However, PET imaging posed a set of challenges that needed to be overcome 
during the study. First of them was the interpretation of the PET image after 
reconstruction, i.e. identifying the tumour position on the image. The reason for 
this initial confusion was that 18F-FLT is non-specific in its way that it labels 
proliferating cells. Because of it all abdominal cavity showed significant signal, 
mostly in the bladder, where the probe metabolites accumulated. In the first 
step then a VOI was drawn around the bladder, threshold set up as described in 
the Methods section and all counts inside were masked. That drastically changed 
the appearance of the image and allowed for distinguishing subtler features in 
that area. The tumour wasn’t readily visible also for another reason, namely, 
because of the signal from mouse intestines, which also proliferate.  
 The way to deal with this interference was to aid the PET image interpretation 
by overlaying it onto CT image. This allowed for broad understanding of the 
placement of major organs. Brain and lungs showed no signal on PET image and 
their position could easily be verified using mouse’s skeleton as an anatomical 
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frame. When it comes to the mouse’s abdomen, however, the soft tissue 
contrast could hardly distinguish individual organs. Visible were the areas of low 
Hounsfield numbers as compared to the surrounding tissues that could be 
interpreted as trapped gas. Tumour position could be approximated looking at 
the outline of the body of the mouse. Knowledge of the mouse anatomy was also 
useful. To start with, healthy pancreas in a mouse can be found below liver and 
stomach and is connected to the duodenum, which in the mouse’s right side. 
Healthy pancreas can be excised from the animal by removing first the intestines 
with which it is connected. Normal spleen is placed below stomach, on mouse’s 
left side. Because all subjects were in advanced stage of their illness, they 
exhibited number of symptoms like abdominal distension. Additionally, their 
tumours grew large enough to have fibrous stroma and often, necrotic core. By 
analysing the area of the image between the approximate position of the liver 
and the bladder, one could often notice how the tumour bulk shifts the bladder 
off its normally central position in the pelvis. When analysing the fused image, 
by connecting the above clues it was possible to confirm that the areas of higher 
signal in untreated mice indeed correspond to the tumour. 
Because the study was the first one to use 18F-FLT in the CR UK Beatson 
Institute, it was necessary to establish imaging protocol that would maximise 
signal-to-noise ratio. One of the ways to do it would be to temporarily inhibit 
the indigenous thymidine in the mouse, so it doesn’t compete with the 
molecular probe administered. This was tried using thymidine phosphorylase 
used clinically to treat patients with solid tumours, but despite due care and 
slow infusion of the drug all three mice died shortly after its administration. The 
reason for it lies most likely in the formulation of the drug that was in a buffer 
solution containing potassium. Although no information could be obtained as to 
the actual potassium content it is very possible that it was sufficiently high to 
dysregulate mouse’s cardiac rhythm that led to its demise. This approach was 
understandably abandoned. 
Due to lack of information in the literature about uptake times and 
pharmacokinetics of 18F-FLT in pancreatic cancer mouse models beyond 60 min, 
it was decided that this should be investigated. The hypothesis was that longer 
uptake time would allow for the probe to accumulate in the target (i.e. tumour) 
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while allowing for its clearance from other organs and therefore improving the 
signal-to-noise ratio. Dynamic scan of the mouse from the time of the i.v. 
injection with 18F-FLT was conducted over the period of 3h after which CT scan 
was acquired. The reason for the scan duration was that Home Office guidelines 
limit the time mouse can be under continuous anaesthesia for up to 4h. Given 
the animals were showing clinical signs of advanced PDAC it was unlikely they 
would survive longer scan anyway. Indeed, two mice died during later scans that 
were shortened to 60 min static acquisition (after 2h uptake time). In the first 
dynamic PET scan conducted, however, mouse successfully recovered from 
anaesthesia after the imaging protocol concluded. In the future studies, it would 
be useful if mouse’s vital signs (e.g. respiration) could be monitored. The tri-
modal Albira PET/SPECT/CT at the time when the study was conducted did not 
offer such option. The only way to monitor an animal was a camera inside the 
scanner, close to the X-ray gantry, which, however, made it difficult to check 
the state of the animal if it was placed properly on the imaging bed, which was 
then closed with a semi-transparent lid. Also, when mouse was being scanned 
using PET, the distance between the imaging subject and the camera was too 
long to check the state of the mouse. For example, if the mouse was showing 
any signs of waking up from the anaesthesia or gasping this was considered  
a signal that the level of anaesthesia is too high. This problem was addressed by 
the manufacturer after the mTOR inhibitor study has concluded. The solution 
offered consisted of the integration of Albira with a third-party modular animal 
monitoring system, which became available as an extra option.  
The time frames in this dynamic study were set to 1 min due to the unknown 
pharmacokinetics of the tracer in these mouse models. The focus was on finding 
the time-point, when the tumour uptake was at its maximum and the tracer is 
cleared from other tissues. The duration of the individual frames had several 
consequences. To start with the study ended with 180 individual list-mode files, 
which needed then to be reconstructed. This was very time-consuming. On the 
other hand, it did allow for the detailed analysis of the tracer biodistribution 
over relatively long period of time.  
Short time frames mean that there was more noise in the reconstructed images 
due to relatively low number of coincidences registered. Furthermore, images 
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were reconstructed using Albira Reconstructor software and the default MLEM 
algorithm. This reconstruction method approximates tracer distribution over the 
selected number of iterations. It uses corrections like random and scattered 
events correction or normalization factor, which corrects for the uneven 
sensitivity within the scanner’s FOV. As it was shown in the spatial resolution 
part of the NEMA protocol discussed in detail in Part I of this work, the best 
spatial resolution of 2-ring Albira PET can be obtained in the middle of one of its 
rings. The further away from that position, the poorer the spatial resolution is 
going to be. This fact was generally considered during all imaging studies 
conducted using Albira PET. However, the main objective of this exercise was to 
obtain biodistribution information, which requires that, if possible, whole body 
of the mouse fits within the FOV. This resulted in the tumour being in sub-
optimal position within the FOV. Since there was a significant signal from the 
probe accumulated in the proliferating intestine, it would be impossible either 
way to draw a VOI reflecting exactly the shape of the tumour. PDAC tumours are 
known to be heterogeneous, which is reflected in the uneven tracer uptake.   
Looking at the biodistribution of 18F-FLT in the PDAC and the liver over the 
period of the pilot scan a trend can be observed with the signal coming from the 
tumour raising and the one from liver slowly. It is possible that scanning the 
animal for even longer period would lead to an improved image contrast. Of 
course, the image would be sharper of the initial activity of the injected 
radiopharmaceutical was higher, so the input from scattered events is relatively 
low. Yet, at the time of the imaging the dose could not be higher than 6 MBq 
(see section 4.1.3 Count-rate Performance in Part I), as otherwise the detectors 
would saturate. The pilot study using dynamic protocol used activity that was 
well within the linear range of the detectors’ count-rate response. Based on the 
results of the pilot study future mice were imaged using static acquisition over a 
period of an hour. Imaging commenced 2h after tracer injection and its dose 
compensated for the 18F decay over this time, so at the time of imaging still 
about 3 MBq of 18F remained in the mouse (minus any excretion in the urine).  
The aim of the study was to investigate a treatment response in two mouse 
models of PDAC. This involved scanning an animal before and after treatment. It 
was impossible to position the mouse on the imaging bed the same twice. 
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Therefore, during an image analysis the tumour wasn’t in the same place and 
could only be identified relatively to the surrounding tissues, which can naturally 
lead to inaccuracies. Furthermore, in both cases the tumour was being outlined 
manually, which is somewhat arbitrary and needed to be validated. Agata 
Mrowinska and Douglas Morran independently conducted their analysis with good 
concordance. Results presented here are those of Douglas Morran. (Morran et 
al., 2014)  
Because CT showed poor contrast of the soft tissues its role in the identification 
of the tumour was limited. This could be improved using contrast agents, in 
particular those targeting liver and gastrointestinal tract. The use of the former 
was tried by Agata Mrowinska using Fenestra Liver Contrast (MediLumine, 
Montreal, Canada formerly known as Advanced Research Technologies; results 
not shown) (Cy et al., 2013), but this was not done for the mice used in the 18F-
FLT study. The latter could be addressed by feeding the mice with barium 
sulphate (e.g. mixing it with peanut butter or drinking water). (Ay & Zaidi, 2006; 
Clark et al., 2015; Wathen et al., 2013) This was not tried. All contrast agents 
need to be carefully titrated to find an appropriate dose (although this is often 
suggested by the manufacturer). Their clearance also needs to be known. 
Fenestra can enhance the liver contrast over 1 day (Suckow & Stout, 2008), but 
care has to be taken in dosing an animal as an allergic reaction to iodine may 
occur. (MediLumine, 2016) Important to note is that any use of CT contrast 
agent with PET should be validated due to the potential of increasing the 
scattering of positrons and hence deteriorate the quality of the PET image. This 
can, however, be partially overcome by using X-ray based attenuation map and 
using it as correction in PET. (Ay & Zaidi, 2006) Unfortunately, the available 
Albira PET did not offer such option although the newer generations of this 
scanner and in particular the 3-ring version of PET provide it. 
Normal pancreas shows a background level of signal in a PET image. This is not 
the case for cancerous lesions. The literature presents conflicting reports 
regarding the usefulness of 18F-FLT in diagnosing or observing a treatment 
response in human pancreatic cancer due to its lower sensitivity than 18F-FDG, 
which is used as standard. (Challapalli et al., 2015; Debebe et al., 2016; 
Herrmann et al., 2012; Mamon et al., 2009; Quon et al., 2008) Herrmann and 
161 
 
colleagues point out that proliferation is not the exclusive feature of pancreatic 
malignancies and can be found also in benign inflammatory lesions of the 
pancreas. This may lead to false-positives. Overall it is more specific radiotracer 
than 18F-FDG and may complement the former in diagnostic and therapeutic 
investigations.   
This study showed that PET imaging with 18F-FLT is a useful tool in comparing 
the proliferation response to mTOR inhibitor rapamacin in KC Pten and KPC 
mice. Specifically, it showed proliferation arrest in the former, but not in the 
latter. This is an evidence that Pten deletion makes tumour rely on the mTOR 
pathway. It is an important finding that can lead to better therapy for a subset 
of patients (ca. 10%) with tumours driven by KRAS mutation and Pten deletion. 
10.2 Gamma Counter Experiments 
In the preparatory experiment the calibration curve of the gamma counter was 
measured. Its results bear significance over the samples that can be then 
measured during animal experiments, i.e. how high and high low activities can 
be measured and is there a linear relationship between the activity of the 
samples and counts registered. The experiment showed that such relationship 
exists (R2 = 0.99 for the energy windows 15 to 2000 keV and 311 to 711 keV, and 
R2 = 0.92 for 822 to 1222 keV). Furthermore, it was important to determine that 
samples with the activities above ca. 300 kBq cannot be resolved by the counter 
as the detectors saturate and the device freezes. This has direct bearing upon 
the dose an animal can be injected with, i.e. if at the time of dissection and 
subsequent measurement any organ contains too high activity, this will not be 
able to be measured, at least not until 18F decays below this threshold.  
The experiment showed also another few issues that had to be considered in the 
later experiments. One of them was that the samples cannot be placed on the 
rack too close to each other as this may cause an interference in the 
measurements. As the rule of thumb, it was established by the previous users 
that 2-3 empty spaces in the cassette are sufficient to avert this. Another 
important consideration is the outdated technology. Although the detector 
electronics may be reliable and of high resolution, it is connected to a PC using 
DOS operating system. This computer displays results on the screen, but only the 
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last 10 of them. They are also printed using a dot-matrix printer, which uses 
special perforated paper. Any problems with the paper feed may result in the 
printing error and lead to a potential risk of losing data. The quality of the print 
also left a lot to be desired for and required some experience in reading the 
numbers off the page. There is no modern communication device that would 
allow for an export of the file containing the results – only a 5 ¼ inch floppy disk 
station. The only way to deal with those challenges was to stay at the gamma 
counter until at least the first sample is counted and the results are sent to a 
printer (meaning also that the sample activity is within the linear range) – if the 
paper feed is even and the print-out readable, other samples can be left 
unattended. When processing the data later using spreadsheet, the accuracy of 
the entered numbers could be verified calculating the ratio of the counts 
measured in the 15 to 2000 keV to 311 to 711 keV – depending on the sample 
volume (discussed below) the ratio should be around 1.7. 
There is no way to predict how much activity will be retained in the tissue after 
a certain uptake time, using a certain radiotracer and an animal model. This 
needs to be verified during pilot experiments or estimated analysing PET images, 
if available. If there are prior PET images, gamma counting ex vivo can serve as 
a tool to validate the PET data and estimate partial volume effect PET images 
may suffer from. In the absence of PET images, such data can still provide 
valuable information about the biodistribution of the probe at a given time-
point. It would be unwise, however, to assume that gamma counting results 
would be immune to sample size or the activity an organ (or piece of it) 
contains. As discussed above, the latter, in case of 18F and the counter used in 
the experiment, is about 300 kBq. On the other hand, the experiment looking at 
the impact of the size volume showed that the relationship between counts 
registered in the widest and the middle energy window (15 to 2000 kBq and 311 
to 711 kBq) follows an exponential decay curve.  
One could expect that the larger the volume of the sample, the more scattered 
the gamma photons become and the more likely they lose they energy and fall 
outside the bottom threshold of the 311to 711 keV energy window (the 
annihilation photons energy peak being 511 keV). In that case the number of 
photons in the 15 to 2000 keV energy window would increase and in 311 to 711 
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keV would decrease. Their ratio therefore would increase with the increasing 
volume. Yet the effect observed is quite the opposite. The decay-corrected and 
averaged results in the latter energy window aggregate around line of negligible 
slope, so within 100 to 1500 μl are nearly constant. However, the counts in the 
15 to 2000 keV energy window decrease as the volume of the sample increases. 
If the number of the photons in the former energy window is unchanged then the 
loss in the total measured photons can be explained by the absorption of the low 
energy photons (below 311 keV) by the sample. Per the plot of count ratio with 
respect to sample volume, the number of the low energy photons increases 
exponentially as the sample size increases. It is worth noting, however, that this 
effect does not depend on the sample activity, since the annihilation photons 
peak energy is also independent of this activity. 
It was calculated that the difference between the maximum and the minimum 
measurement in the 311 to 711 keV energy window within the range of activities 
measured was less than 5%. This energy window therefore yields the least 
variable results and it is the reason why it was chosen as the reference window 
in the 18F-FLT biodistribution experiments.   
10.3 TGFβ 
The aim of the study was to investigate if the addition of TGFβ antibody to 
gemcitabine, which is for now still considered a “golden standard” in the 
treatment of pancreatic cancer, improves the efficacy of such treatment. The 
surrogate outcome in which it was assessed was proliferation, which is one of 
the processes controlled by the PI3K pathway in which TGFβ plays an important 
role. Proliferation was measured in three different ways. Animals were injected 
with 18F-FLT and the biodistribution of the probe in all main organs harvested 2h 
after injection was measured using gamma counting. Next, parts of the frozen 
pancreatic and liver tissues were cut and exposed overnight to photographic film 
in autoradiography study. Finally, the remaining parts of those tissues were fixed 
in buffered formalin, paraffin embedded, cut and Ki67 IHC performed. 
There is not enough evidence that would indicated that statistically significant 
difference between the biodistribution of 18F-FLT as measured by gamma 
counting among the treated and untreated cohorts of mice exists or does not 
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exist. An organ that showed the smallest retention of the probe was brain and 
the highest was measured for large and small intestine. This is consistent with 
the expected level of proliferation in those organs, also in a healthy animal. The 
level of signal measured for the tumour was like the one of spleen, stomach, 
liver or blood and varied little between groups treated with gemcitabine or with 
added TGFβ antibodies. This did not differ from the untreated group, which is 
unexpected since gemcitabine interferes with DNA synthesis (and hence 
proliferation) and induces apoptosis. One of the explanations could be that 
benefits of gemcitabine treatment can be observed in the longer time-scale and 
after treatment that involves constant, but small dosing of the drug, and not 
acutely, 24h after intraperitoneal injection.  
The lack of obvious difference among the experimental groups can also possibly 
be attributed to mice being at different stages of the disease development. 
Although all due care was taken to select only animals with palpable tumours, at 
necropsy the disease advancement proved to vary vastly – some mice had 
obvious, large tumours with fibrous stroma, but some seemed to have no tumour 
at all and only proved to be at early stages of carcinoma when IHC was 
performed. Also, some animals were showing co-morbid conditions like blocked 
bile-duct, lymphoma or additional lung cancer. It might be that the actual effect 
of the investigated therapy will only emerge once the cohorts are further 
enlarged, so such animals can be excluded from the analysis or when there is 
sufficient number of those with such conditions that they can be analysed as 
separate sub-groups.  
Alternatively, since TGFβ is known to play two different roles in the cancer 
development, the effect would be prominent if mice could be divided for the 
cancer stage. However, this would be very difficult to achieve using KPC mouse 
model as it is challenging to select animals at the early stage of the disease and 
additionally, animals in late stages have very limited life-expectation and may 
need to be euthanized prematurely for ethical reasons. Some animals had also 
distant metastasis, which further changes the picture of the summary. The level 
of the disease development is probably the largest contributing factor in the 
variability in the experiment, mainly because the role of TGFβ changes as the 
cancer advances. It could be that by introducing TGFβ antibody in the early 
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stages the pace of cancer progression was increased as the cancer-suppressive 
properties of TGFβ were inhibited. On the other hand, in late stages of the 
disease the variety of co-morbid conditions may impact in how the TGFβ 
antibody is distributed in the body. It might be that it shows affinity to receptors 
in other sites than pancreatic tumours.  
The dose of the antibody could also be inadequate in late stages of the disease. 
The dose used in the experiment was the same as one used in the (unpublished) 
pilot study performed in the CR UK Beatson Institute. It could be that titration of 
the drug is needed to establish the minimal working dose. However, the aim of 
the study was not to find the dose that would impact mouse survival, but rather 
to establish if introducing TGFβ antibody has any impact on proliferation 
whatsoever.  
During the experiment a problem arose with the availability of the TGFβ 
antibody that was being used. After discussion with the manufacturer, an 
alternative was selected and the study was continued using the new antibody. 
Although very little difference was observed between mice treated with either 
antibody it would certainly improve the statistical power of the study if the 
same antibody could be used throughout the whole study.  
It could also be that no effect was observed, because the antibody does not 
reach the site of interest. The antibody was optimised to be used in other 
applications like Western Blotting and/or IHC, but not necessarily in the in vivo 
study. It could be that it is broken down or otherwise metabolized before it has 
a chance to bind to the receptors in the cancer site when introduced via an 
intraperitoneal injection. The way to answer that would be to perform IHC using 
the antibody to see if there is any difference in IHC expression among treated 
and un-treated cohorts. However, even if the antibody binds to the receptor, 
TGFβ activity should be confirmed. This could be done by investigating the 
activity of the downstream proteins in the SMAD pathway (e.g. SMAD2, SMAD3) 
and in the PI3K/AKT pathway (e.g. Src, S6 kinase).  
The study looked at the acute effect of antibody on proliferation, i.e. at 24±2h 
post-injection. It is likely that any longer than that and the antibody is 
completely cleaved from the receptor and the latter returns to the base-line 
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state. It could be, however, that at shorter time-point the observed effects is 
greater and that to bring benefit, mouse would need to be treated at shorter 
time intervals, which is problematic when it comes to animal welfare (even if 
the stress induced by frequent treatment is considered) and cost-effectiveness 
antibody-treatment being much costlier than chemotherapy. 
It would be beneficial if all mice in the study were investigated using the same 
techniques. This was not, however, possible for independent reasons, e.g. after 
selected mice were treated the day before, 18F-FLT synthesis was not always 
possible due to equipment failure. Also, some mice had to be euthanized before 
they could be used in the study and the necropsy showed that their poor 
condition was caused by the cancer-related condition like lymphoma or blocked 
bile duct. 
It proved challenging to inject animals with enough 18F-FLT, so after 2h (plus the 
time needed for the dissection) the level of signal from each sampled organ 
would be high enough (but too high) to perform gamma counting and 
autoradiography. Care had to be taken here not to inject animal with volume 
larger than 200 μl and ensuring that all animals studied on the day were injected 
with the same activity. The last of three mice was always injected with the 
highest volume due to the radiotracer decay and using this volume as a 
guideline, the maximum dose for other two mice was calculated. 
Although the study design entailed sacrificing mice after treatment such 
approach requires use of much larger cohort of mice to achieve the same 
statistical power than if each mouse was its own control. This could only be 
achieved if some sort of functional imaging technique in vivo could be used. As 
such, PET imaging using proliferation marker like 18F-FLT would be particularly 
helpful. Unfortunately, at the time the study was conducted, Bruker Albira 
PET/SPECT/CT scanner was decommissioned and could not be used and this is 
part of the reason why alternative techniques were used. The other reason for 
the use of gamma counting and autoradiography was that they can be used as ex 
vivo validation techniques of PET since all three are based on the use of radio-
labelled probe. Ki67 IHC was used because it is an alternative way of measuring 
proliferation and, at least in theory, should provide the same answer to the 
aforementioned.  
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Out of the three ways of measuring proliferation, autoradiography proved to be 
the least-informative. The contrast between the background and the tissue was 
low and images of the sections proved to be of low resolution that would not 
reflect tumour heterogeneity. Perhaps if the mouse was injected with higher 
activity this could be partially alleviated, but using sensitive photographic film 
risks bleaching in the over-exposed regions. This was observed when one of the 
mice was accidentally injected with 18F-FLT subcutaneously in the tail and, as a 
result, the dose must have been being absorbed over longer period of time than 
if it would otherwise be the case (data not shown). 
Ideally also it would be useful if autoradiography slices could be compared 1:1 
with Ki67-stained ones. This could be achieved by cutting pairs of adjacent 
frozen sections and then using one of them for autoradiography and another one 
for frozen Ki67 staining. This was attempted at the first experiments, where the 
latter stage was performed using automatic protocol on Dako Autostainer. 
Unfortunately, the IHC on frozen sections proved unsuccessful (the tissue 
sections were peeling off the slide) and this direction was eventually abandoned 
in favour of the formalin-fixed and paraffin-embedded sections from the other 
half of the tissue sample. This provided valuable high-resolution insight into the 
tissue morphology in cases, where gross pathology could not point to an obvious 
solid tumour. Yet, since PDAC tumours are known from their heterogeneity it 
could be that autoradiography and IHC samples were inadvertently taken from 
sites unequally affected by the disease. In that respect IHC and gamma counting 
samples could theoretically be compared more closely, because those 
measurements were taken using the same pieces of tissue. However, Ki67 
staining was performed on a single section, 4 μm-thick, which may not represent 
well the rest of the sample. If one were to compare the correlation between 
Ki67-staining and gamma-counting results, whole piece of tissue should be sliced 
and stained. Although time-consuming, this Is possible, albeit does not 
guarantee better accuracy of the results or definitive answer to the question 
posed. 
Certainly, what would improve the statistical power of the results is if all mice 
in the study could be evaluated using all three techniques. Unfortunately, 
despite the best efforts some data was lost due to equipment failures (e.g. 
168 
 
failure of the GE FastLab to produce 18F-FLT, error in the X-ray film processor).  
The biggest challenge remained, however, in the time needed to process one 
mouse from the moment of the tail-vein injection to the time of submission of 
the samples to the Histology Department for fixing, embedding in paraffin, 
cutting and staining for Ki67. Even when the injection of the mice was 
staggered, this would only allow for processing of maximum of three mice on any 
given day. Partially this constraint stems from the limited volume the mouse can 
be injected with. Mainly, however, it was a result of the actual time needed to 
harvest all the samples, freeze them, transport them out of the animal facility 
and to the laboratory holding the gamma counter. Further, time was needed to 
cut the frozen tissues and apply the X-ray film in the dark room placed in the 
far-end part of the building.  
Biodistribution data show that no trends could be discerned among the 
accumulation of 18F-FLT or its metabolites in the sampled organs, but provides 
insight into the behaviour of the used probe that can be useful when planning 
another study using the same mouse model and/or PET imaging study. If the 
latter was available, a comparison could be made between apparent activity 
concentration and one that was measured using gamma counter. In general, 
gamma counter is more sensitive, while in PET part of the signal is lost due to 
the scanner geometry and detector technology, which at the moment can, at 
best, register 9-10% of all annihilation events. Additionally, PET suffers from 
partial volume effect, which may lead to over- or underestimation of the actual 
activity concentration in the given organ. This may be significant if one were to 
compare pre- and post-treatment images of a subject. The only way to avoid it 
would be to excise the organ and measure it using an independent technique 
(e.g. gamma counter). However, the advantage of PET over ex vivo 
measurements is that it allows for longitudinal studies and monitoring the 
progression of the disease, where subject is its own control over the period. 
The normalized results for each organ (which considered the administered dose 
of 18F-FLT, weight of the mouse and time that elapsed between administration 
of 18F-FLT and measurement) were analysed using lima package in R-software. 
These did not correlate with the treatment a mouse was subject to in a 
significant manner in any of the sampled tissues. For the sake of saving time if 
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the experiment was to be repeated or continued, only PDAC and liver tissues 
could be harvested and tested. This would most likely allow for processing of 
more than 3 mice per experiment. However, KPC mice are not easily available 
and develop cancer spontaneously from the age of 10-weeks onwards. This 
complicates the logistics-side of the matter, because at the time experiment is 
due, there can be problems in finding suitable number of animals that would 
show clinical signs of locally advanced disease. It can only be achieved if one 
were to keep large cohort of animals of different ages, which is costly and does 
not guarantee success. Also, because the pancreata of mice have mesenteric and 
not a solid structure (like in humans), which wraps around intestine, it is 
possible and relatively easy (especially for an unexperienced person) to 
misdiagnose an animal. Namely, during the palpation of the mouse’s abdomen 
one may assume the existence of a tumour, where in fact it is the bowel 
movement. The way to avoid it would be to seek opinion from more experienced 
persons, use another technique to visualise the contents of the abdominal cavity 
(like ultrasound) or try to palpate the tumour the next day (bowel movement 
will most likely be gone by then while tumour will rather stay in the same 
place). In some cases, where mouse is expressing also fluorescent or 
bioluminescent proteins in the cancer cells (a derivative model from KPC) 
fluorescence or bioluminescence imaging techniques may also provide a way to 
pre-screen animals for the experiment. Their downside is that they are not very 
useful when the tissue of interest is deeper than few millimetres in the body and 
that the measured signal is proportional to the number of cancer cells. This has 
obvious limited application when looking for animals at the early stages of the 
disease. Of course, at later stages, the clinical signs are quite easily noticeable, 
but what causes problems then are the co-morbid conditions, which can be 
equally fatal to the mouse if left unattended (e.g. lymphoma, blocked bile duct 
etc.). This is the reason why some mice needed to be euthanized before they 
could be enrolled in the study and why data from the remaining ones is loaded 
with extra noise as some conditions were only diagnosed post-mortem. 
The aim of the study was to compare the cohorts of mice treated with 
gemcitabine and TGFβ antibody, and gemcitabine only. The results do not show 
clear advantage of the former upon monotherapy. Interestingly, compared to 
the untreated cohort, gemcitabine does not show to make significant difference 
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in the proliferation levels in any of the assessed organs nor using any of the 
measurement techniques applied.  
The source of additional experimental noise could also be from the genetic 
background of the mice used. Specifically, most of the mice were of “pure” KPC 
phenotype, but additionally expressed green fluorescent protein (GFP) and 
ecadherin genes in the Pdx-1 progenitor cells. The latter were used in the 
experiment since they show the same clinical signs and at the same timescale as 
“normal” KPC mice. There is a possibility, however, that the extra proteins 
produced by the cancer cells interfere somehow with the drugs and/or 18F-FLT 
administered. This could be investigated further if larger cohorts of mice of both 
genotypes were available. At the basic level of data analysis (data not shown), 
there was no apparent different between the groups, hence they were pooled 
into one group to represent KPC mice. 
The fact that no significant difference was observed in the series of experiments 
described above could be simply since the effect was too small to be observed 
due to the noise level. Alternatively, the time at which the proliferation was 
measured could be sub-optimal. The 2h uptake time was based on the results of 
the mTOR PET imaging experiment discussed above. Yet, in this experiment KC 
Pten mouse was imaged and the whole uptake period was taking place under 
anaesthesia. The 2h post-18F-FLT administration time was chosen, because KC 
Pten and KPC resemble each other in clinical signs and how the disease 
progresses. The anaesthesia would slow down the metabolism of the mouse, but 
should not have much impact upon proliferation.  
The conclusion is that within the given time-scale and using the applied 
techniques no proliferation-inhibitory advantage of adding TGFβ antibodies to 
gemcitabine was observed. This does not mean that this treatment approach 
would not improve survival rates or otherwise limit the metastatic spread. The 
available results assess the effects of a single treatment 24±2h after. This was 
deemed as “acute” response to treatment, while in fact there is no data 
investigating proliferation rates at different time-points or measuring the effects 
of TGFβ antibodies administration over a time alone or in conjunction with 
gemcitabine. It could be that the TGFβ antibody does aid the proliferation 
inhibition, but only over much shorter time after which its rate returns to the 
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baseline. Alternatively, there could be a benefit in using TGFβ antibodies 
(preferably as a course of treatment) not only to inhibit proliferation, but to 
help with desmoplasia. If the latter was achieved, this could help in the drug 
delivery into the tumour. There could also be more effective TGFβ inhibitors 
(other than antibodies) that could yield better results.  
TGFβ remains an attractive, yet somewhat elusive therapeutic target. Due to its 
complex interactions with other proteins and involvement in the variety of 
pathways activated in cancer, it will take time before we understand its role 
fully. The series of experiments presented aimed at only one of its facets, 
namely proliferation. We investigated the effect of TGFβ inhibition in the in vivo 
environment and this work can now provide a good background data that can 
help in future imaging studies using 18F-FLT in the pancreatic cancer mouse 
models.
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11 Conclusions 
As a molecular imaging technique PET became an important tool aiding the 
diagnosis and assessment of the treatment efficacy in cancer and other illnesses. 
With the improvements in the detector technologies and image reconstruction 
small-animal PET can currently produce images of a sub-millimetre spatial 
resolution and sensitivity approaching 10%. This makes it invaluable tool in pre-
clinical in vivo research of novel radiopharmaceuticals, drug development and 
improving our understanding of mechanisms driving various diseases. In this 
work, I characterised the performance of PET and CT components of Albira 
PET/SPECT/CT – a tri-modal small-animal scanner, which proved it to be 
sufficient for mice imaging. 
I then considered the use of 18F-FLT as a proliferation marker allowing for the 
characterisation of the treatment response in two mouse models of PDAC. In the 
first study, we have shown that rapamycin, an mTOR inhibitor brings therapeutic 
benefits like proliferative arrest (measured using 18F-FLT PET and Ki67 IHC) and 
improved survival in KC Pten, but not KPC mice. In the TGFβ antibody study 
untreated, gemcitabine-treated, and gemcitabine and TGFβ antibody-treated 
mice were compared using gamma counting, autoradiography and Ki67 IHC. None 
of those techniques showed significant difference to proliferation. 
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12 Appendix 
Mouse record sheet 
Date:  Mouse ID:  Strain:  
Previous PPL:  Mouse sex:  Weight [g]:  
Doses 
Prepared: MBq At (time)  In (volume) μl 
Left: MBq At (time)    
Injected MBq At (time)  Animal sacr.:  
 
Gamma counting:  
Counting started: _________________ Protocol number: ______7______ 
Vial ID Tissue W. before [g] W. after [g] Tissue [g] 
Counts 
/1min 
 Blood     
 Heart     
 Lungs     
 Spleen     
 Kidney     
 Stomach     
 SG     
 LG     
 PDAC/pancreas     
 Liver     
 Muscle     
 Brain     
 Ctrl1     
 Ctrl2     
 Ctrl 3     
      
      
Autoradiography: 
Cutting started: _________________ Film applied: ______________ 
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